

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Impact of maternity waiting homes on facility delivery among remote households in Zambia: protocol for a quasi-experimental, mixed-methods study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022224
Article Type:	Protocol
Date Submitted by the Author:	07-Feb-2018
Complete List of Authors:	Scott, Nancy; Boston University School of Public Health, Global Health Kaiser, Jeanette; Boston University School of Public Health, Global Health Vian, Taryn; Boston University School of Public Health, Global Health Bonawitz, Rachael; Boston University School of Public Health, Global Health; Boston University School of Medicine, Pediatrics Fong, Rachel; Boston University School of Public Health, Global Health Ngoma, Thandiwe; Right to Care Zambia Biemba, Godfrey; National Health Research Authority, Pediatric Centre of Excellence Boyd, Carol; University of Michigan School of Nursing, Health Behavior & Biological Sciences Lori, Jody; University of Michigan School of Nursing, Center for Global Affairs & PAHO/WHO Collaborating Center Hamer, D.; Boston University, Rockers, Peter; Boston University, Department of Global Health
Keywords:	maternity waiting home, maternal health, facility delivery, mixed methods, impact evaluation, Zambia

SCHOLARONE™  
Manuscripts

**Title:** *Impact of maternity waiting homes on facility delivery among remote households in Zambia: protocol for a quasi-experimental, mixed-methods study*

**Authors:**

Name	Institutional Address	Email Address
Nancy Scott	Department of Global Health, Boston University School of Public Health, Boston, USA 801 Massachusetts Ave, Boston, MA 02118	<a href="mailto:nscott@bu.edu">nscott@bu.edu</a> (corresponding) Tel: +1-617-414-1278
Jeanette Kaiser	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:jkaiser@bu.edu">jkaiser@bu.edu</a>
Taryn Vian	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:tvian@bu.edu">tvian@bu.edu</a>
Rachael Bonawitz	Department of Global Health, Boston University School of Public Health Boston, MA USA Department of Pediatrics, Boston University School of Medicine Boston, MA USA	<a href="mailto:rebonawi@bu.edu">rebonawi@bu.edu</a>
Rachel Fong	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:rmfong@bu.edu">rmfong@bu.edu</a>
Thandiwe Ngoma	Right to Care-Zambia Lusaka, Zambia	<a href="mailto:ngoma.thandiwe@gmail.com">ngoma.thandiwe@gmail.com</a>
Godfrey Biemba	National Health Research Authority, Pediatric Centre of Excellence Lusaka, Zambia	<a href="mailto:gbiemba@gmail.com">gbiemba@gmail.com</a>
Carol J. Boyd	Department of Health Behavior & Biological Sciences School of Nursing, University of Michigan Ann Arbor, MI USA	<a href="mailto:caro Boyd@med.umich.edu">caro Boyd@med.umich.edu</a>
Jody R. Lori	Center for Global Affairs & PAHO/WHO Collaborating Center School of Nursing, University of Michigan Ann Arbor, MI USA	<a href="mailto:jrlori@umich.edu">jrlori@umich.edu</a>
Davidson H. Hamer	Department of Global Health, Boston University School of Public Health Boston, MA USA  Section of Infectious Diseases, Department of Medicine, Boston Medical Center Boston, MA USA	<a href="mailto:dhamer@bu.edu">dhamer@bu.edu</a>
Peter C. Rockers	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:prockers@bu.edu">prockers@bu.edu</a>

**Word count:** 4,200 (excluding title page, abstract, references, figures and tables)

## List of Acronyms

Africare/UM	Africare/University of Michigan
ANC	Antenatal care
BEmONC	Basic emergency obstetric and newborn care
BU/RTC	Boston University/Right to Care Zambia
CBA	Controlled before-and-after
CEmONC	Comprehensive emergency obstetric and newborn care
GRZ	Government of the Republic of Zambia
HHS	Household survey
IDI	In-depth interview
IRB	Institutional review board
MHA	Maternity Homes Alliance
MMR	Maternal mortality ratio
MSD	Merck Sharp & Dohme
MWH	Maternity Waiting Home
PNC	Postnatal care
SDG	Sustainable Development Goals

## ABSTRACT

**Introduction:** Maternity waiting homes (MWHs) aim to improve access to facility delivery in rural areas, especially among women living farthest from health facilities. However, there is limited rigorous evidence of their effectiveness. Using formative research, we developed a MWH intervention model with three components: infrastructure, management, and linkage to services. We present a protocol for a study that aims to measure the impact of the MWH model on facility delivery among women living  $\geq 10$ km from their designated health facility in rural Zambia.

**Methods and analysis:** We are conducting a mixed-methods quasi-experimental impact evaluation of the MWH model using a controlled before-and-after design in 40 health facility clusters. Clusters were assigned to the intervention or control group using two methods: 20 clusters were randomly assigned using a matched-pair design; the other 20 were assigned without randomization due to local political constraints. Overall, 20 study clusters receive the MWH model intervention while 20 control clusters continue to implement the 'standard of care' for waiting mothers. We recruit a repeated cross-section of 2,400 randomly sampled recently-delivered women at baseline (2016) and endline (2018); all participants are administered a household survey and a 10% subsample also participates in an in-depth interview. The primary outcome is the probability of delivery at a health facility; secondary outcomes include utilization of MWHs and maternal and neonatal health outcomes.

**Ethics:** Ethical approvals were obtained from the Boston University Institutional Review Board (IRB), University of Michigan IRB (for de-identified data only), and the ERES Converge IRB in Zambia. Written informed consent is obtained prior to data collection.

**Conclusion:** To the best of our knowledge, Zambia is the first country to rigorously evaluate the impact of MWHs on women living most remotely. This study will generate key new evidence to inform decision making for MWH policy in Zambia and globally.

**Trial Registration:** ClinicalTrials.gov Identifier: NCT02620436

**Keywords:** maternity waiting home, maternal health, facility delivery, mixed methods, impact evaluation, Zambia

## ARTICLE SUMMARY

### Strengths and limitations of this study

This study has several strengths and limitations, including:

- To the best of our knowledge, this is the first large-scale impact evaluation of MWHs, employing a rigorous controlled before-and-after, quasi-experimental design and using mixed-methods.
- For generalizability, a representative sample of recently-delivered women living most remotely is selected using a multi-stage, random sampling strategy for both the quantitative household surveys and the qualitative in-depth interviews.
- Half of study clusters could not be randomly assigned to either the intervention or control group due to political constraints, resulting in quasi-experimental study design.
- Because remote women stand to benefit the most from the MWH model, eligibility is limited to those living at least 10km from the health facilities; findings will therefore not be able to assess impact of the intervention on women living nearer to facilities.
- In companion protocols, implementation fidelity of the core elements of the MWH model is assessed by each partner using harmonized tools.

## INTRODUCTION

The Sustainable Development Goals (SDGs) include a target of reducing the global maternal mortality ratio (MMR) to less than 70 deaths per 100,000 live births by 2030.[1] Zambia's MMR is currently 398 deaths per 100,000 live births, well above the SDG target.[2,3] Skilled care at every birth, one of the two SDG indicators for MMR, is recommended. What remains unanswered is how to best facilitate access to intrapartum and postpartum care, particularly in rural and remote areas where distance and poor transportation severely restrict access to care. The Government of the Republic of Zambia (GRZ) is committed to improving maternal health and encourages facility-based delivery for all women,[4,5] though accessing facilities for birth is challenging for women living in remote areas.[6,7]

Maternity waiting homes (MWHs) are lodgings located near health facilities where mothers who are close to term can await delivery. MWHs are meant to provide pregnant women with the option of planning ahead and traveling to health facilities well before labor begins. MWHs may be a promising strategy to improve access to facilities for delivery, though there is limited rigorous evidence of their effectiveness on improving rates of facility delivery, particularly among women living remotely. While some evidence suggests MWHs are associated with higher rates of facility delivery and improved maternal health outcomes,[8,9] a Cochrane review found that there are no randomized or quasi-randomized trials assessing the effectiveness of MWHs in low-resource settings.[10] Rigorous evidence on the impact of MWHs on facility deliveries is needed.

This protocol describes a study being conducted by the Maternity Homes Alliance (MHA), a partnership between the GRZ, Boston University and Right to Care Zambia, formerly the Zambian Center for Applied Health Research and Development (BU/RTC), Africare and the University of Michigan (Africare/UM), and funded by Merck Sharp and Dohme (MSD) for Mothers, the Bill & Melinda Gates Foundation, and The ELMA Foundation. The MHA hypothesizes that MWHs can remove the distance barrier and increase access to facility-based delivery. In this study, we test the impact of MWHs on

1  
2  
3 facility delivery among women living at least 10km from health facilities in rural Zambia. To the best of  
4  
5 our knowledge, this is the first study to rigorously evaluate the impact of MWHs on those living most  
6  
7 remotely. This study will generate findings that contribute to the global knowledge of MWHs.  
8  
9

## 10 **Intervention**

11  
12  
13 Formative evaluations conducted previously by members of the study team in the current study  
14  
15 setting showed that MWHs could be an acceptable and feasible option to improve access to facilities for  
16  
17 delivery.[11–13] An MWH model, developed based on these findings, was designed to be responsive to  
18  
19 community standards of acceptability including safety, comfort, and services offered in accordance with  
20  
21 local input (Figure 1). The MWH model is community-owned and operated as per the request of  
22  
23 government officials, but is operationally affiliated with the local health facility and is situated near the  
24  
25 facility. Routine antenatal care (ANC) and other clinical services continue to be provided at the health  
26  
27 facility, not in the MWH. The MWH model targets all pregnant women within 1-2 weeks of their  
28  
29 estimated delivery date resident within the catchment area, prioritizing those women living farthest  
30  
31 away (i.e. > 10 km from the health facility).  
32  
33  
34  
35

36 **INSERT FIGURE 1**

## 37 38 39 40 41 **METHODS AND ANALYSIS**

### 42 43 44 **Evaluation questions**

45  
46 The primary research question is:

- 47  
48  
49 1. What is the impact of the MWH model on the probability of facility delivery among mothers  
50  
51 living more than 10 km from the facility?  
52

53  
54 Secondary evaluation questions include:  
55  
56  
57  
58  
59  
60



- 1  
2  
3 1. Do awareness and perceptions of health facility-associated safe delivery and health facility  
4 delivery intention among pregnant women living in communities located more than 10 km from  
5 the health facility change over time in MWH model sites?  
6  
7
- 8  
9 2. How do awareness and perceptions of MWHs by communities located more than 10 km from  
10 the health facility change over the period of this study?  
11  
12
- 13 3. What financial impact does the use of the MWH model have on the families of women who  
14 utilize it?  
15  
16
- 17 4. How does the perception of quality of care differ between MWH model sites and control sites?  
18  
19
- 20 5. What is the impact of the MWH model on maternal and neonatal health outcomes among those  
21 living more than 10 km from the facility?  
22  
23  
24  
25

### 26 **Study setting**

27  
28  
29 The intervention and comparison sites are located in the primarily rural Zambian districts of  
30 Choma, Kalomo and Pemba Districts of Southern Province; Nyimba and Lundazi Districts of Eastern  
31 Province; and Mansa and Chembe Districts of Luapula Province (Figure 2).  
32  
33  
34

### 35 **INSERT FIGURE 2**

36  
37  
38  
39  
40 Choma district has a population of 247,860 and a population density of 34/km<sup>2</sup>, with 68.7% of its  
41 population being rural. Kalomo district has a population of 258,570 and a population density of  
42 17.2/km<sup>2</sup>, with 91.8 percent of its population being rural.[14] Nyimba district has a population of 85,025  
43 and a population density of 8.1/km<sup>2</sup>, with 91 percent of its population being rural. Lundazi district has a  
44 population of 323,870 and a population density of 23/km<sup>2</sup>, with 95.1 percent of its population being  
45 rural.[15] Mansa district has a population of 228,392 and a population density of 23.1/km<sup>2</sup>, with 61.9  
46 percent of its population being rural.[16]  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Study design

This study employs a quasi-experimental controlled before-and-after (CBA) design with a total of 40 study clusters. Clusters are comprised of health facilities and their catchment households. Twenty intervention clusters receive the MWH model and 20 control clusters in the same districts continue to implement the 'standard of care' for waiting mothers. The current standard of care at facilities for waiting expectant mothers varies across Zambia: some have no designated space for a mother to wait; others have no MWH but provide a designated space for waiting mothers within the clinic; and a small number have an existing MWH-like structure but with highly variable quality.[9] Clusters were assigned to the intervention or control group using two methods: 20 clusters were randomly assigned (10 intervention and 10 control) using a matched-pair design, while the other 20 were assigned (10 intervention and 10 control) without randomization due to local political constraints (Table 1).

**Table 1:** Quasi-experimental study design to evaluate the impact of MWHs

Randomized subsample (n=20 clusters)	Non-randomized subsample (n=20 clusters)	Non-randomized full sample (n=40 clusters)
R O1 X O2	NR O1 X O2	NR O1 X O2
R O1 _ O2	NR O1 _ O2	NR O1 _ O2

*X = Minimum Core Maternity Home (see above)*

*O = Observations at baseline (O1, in 2016) and endline (O2, in 2018) at intervention (X) and comparison ( \_ ) sites.*

*R = cluster randomized; NR = not randomized*

## Eligibility criteria of study sites

The MWH model is being implemented at 20 rural health facilities capable of managing basic emergency obstetric and neonatal complications (BEmONC). Facilities were eligible for inclusion in the study if they met at least one of two sets of conditions:

### Eligibility condition set 1:

- i. Able to provide at least 5 of 7 BEmONC signal functions;

- 1
- 2
- 3 ii.  $\leq 2$  hours travel time to a comprehensive emergency obstetric and neonatal care (CEmONC)
- 4 capable referral facility;
- 5
- 6
- 7
- 8 iii. Performs a minimum of 150 deliveries per year.
- 9
- 10
- 11

12 Eligibility condition set 2:

- 13
- 14 i. Has at least one skilled birth attendant on staff;
- 15
- 16 ii. Routinely provide active management of third stage of labor;
- 17
- 18 iii. Has had no stock outs of oxytocin in the last 12 months;
- 19
- 20
- 21 iv. Has had no stock outs of magnesium sulfate in the last 12 months;
- 22
- 23
- 24 v. Located within  $\leq 2$  hours travel time to a CEmONC referral facility.
- 25
- 26
- 27

28 For the randomized subsample, 20 clusters were matched in pairs based on transfer time to  
29 CEmONC and clinic delivery volume. One cluster within each matched pair was then randomly selected  
30 to receive the intervention using the RAND function in Excel, yielding 10 intervention sites and 10  
31 control sites. In the non-randomized subsample, 10 clusters were purposively selected to receive the  
32 intervention based on a consultative process with local stakeholders. Ten matched clusters were then  
33 identified from the full set of health facilities in the study districts based on transfer time to CEmONC  
34 and facility delivery volume.  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 **Data sources**

45  
46  
47 Population data are being collected from two main sources: household surveys (HHS) and in-  
48 depth interviews (IDIs). Baseline data collection occurred in early 2016 prior to the implementation of  
49 the MWH model in intervention clusters; endline data collection will occur in late 2018, after an 18  
50 month intervention period. The HHS is administered to a sample of 2,400 recently delivered women  
51 (eligibility criteria described below) residing in intervention and control clusters. In the case of maternal  
52  
53  
54  
55  
56  
57  
58  
59  
60

death, the household head or senior woman was interviewed as a proxy respondent. The HHS captures information on the domains and data fields seen in Table 2.

**Table 2.** Summary table of data fields collected from the household survey

<b>Household Panel:</b>	<ul style="list-style-type: none"> <li>• Geo-coordinates of household/distance from nearest health facility</li> <li>• Age and sex of household members</li> <li>• Education level of household members</li> <li>• Recent pregnancy/delivery of household members</li> </ul>
<b>Individual Demographics and Household Characteristics</b>	<ul style="list-style-type: none"> <li>• Number of pregnancies</li> <li>• Outcome of pregnancies</li> <li>• Number of living/deceased children</li> <li>• Characteristics of living quarters (e.g., roof type, floor type, cooking fuel type)</li> <li>• Access to and quality of water</li> <li>• Household wealth indicators and assets</li> </ul>
<b>Last Pregnancy</b>	<ul style="list-style-type: none"> <li>• Antenatal services utilized</li> <li>• HIV testing               <ul style="list-style-type: none"> <li>○ Status</li> <li>○ PMTCT*</li> </ul> </li> <li>• Perceived quality/satisfaction with Antenatal</li> </ul>
<b>Last Delivery</b>	<ul style="list-style-type: none"> <li>• Location of last delivery               <ul style="list-style-type: none"> <li>○ Decision-maker in location of delivery</li> <li>○ Mode of transportation</li> </ul> </li> <li>• Referral and bypassing</li> <li>• Receipt of CEmONC services (C-section, blood transfusion)</li> <li>• Perceived quality/satisfaction with delivery services</li> <li>• Maternal and neonatal outcomes</li> </ul>
<b>Use of Mother's Shelter</b>	<ul style="list-style-type: none"> <li>• Knowledge of mother's shelter</li> <li>• Nearest mother's shelter to home</li> <li>• Use of mother's shelter before/after last delivery               <ul style="list-style-type: none"> <li>○ Cost of using mother's shelter</li> <li>○ Perceived quality of mother's shelter</li> <li>○ Satisfaction with mother's shelter</li> </ul> </li> </ul>
<b>Cost of Delivery and Delivery Planning</b>	<ul style="list-style-type: none"> <li>• Planned location for delivery               <ul style="list-style-type: none"> <li>○ Adherence to planned location for delivery</li> </ul> </li> <li>• Savings for last delivery</li> <li>• Cost of last delivery (broken down by expense)</li> </ul>
<b>Postnatal Care (PNC)</b>	<ul style="list-style-type: none"> <li>• Time to first maternal and newborn post-natal visit after delivery</li> <li>• Perceived quality of post-natal services received</li> <li>• Breastfeeding practices</li> <li>• Supplementary feeding practices</li> <li>• Newborn vaccination</li> </ul>

	<ul style="list-style-type: none"> <li>• PMTCT/ART<sup>++</sup> for newborn</li> <li>• Interactions between the parent and the child</li> <li>• Maternal depression assessment</li> <li>• Health seeking behavior for child's last illness</li> </ul>
<b>Health Care Knowledge and Beliefs</b>	<ul style="list-style-type: none"> <li>• Use of contraceptive</li> <li>• Primary barriers to accessing health care             <ul style="list-style-type: none"> <li>○ Primary barriers to accessing skilled delivery services</li> </ul> </li> </ul>

\*PMTCT = Prevention of mother-to-child transmission of HIV; \*\*ART = Antiretroviral therapy

In-depth interviews are conducted among a subsample of 240 HHS respondents in order to gain a deeper understanding of community awareness, perceptions and experiences. Content includes perceptions of labor and delivery practices, barriers to accessing care, knowledge and awareness of MWHs, perceptions of the quality of maternity homes (guided by the MWH model), perceptions of MWH ownership, perceptions of quality of care at the facility, and expenses incurred for last delivery.

The population-based approach captures the experiences of those who utilized the facility in their catchment, other facilities, and those who did not access a facility for delivery, allowing us to more accurately estimate the impact of the MWH model intervention among women living farthest from the health facility.

### Sampling strategy and sample size

We recruit a repeated cross-section of 2,400 households at each round for the survey (approximately 60 households per cluster): 1,200 from both intervention and control sites at both baseline (completed in 2016) and endline (planned for 2018), for a total study sample of 4,800 households (Table 3). After accounting for the clustered sampling design (ICC estimated at 0.04 based on previous work [17–19]), and assuming an alpha of .05, this sample will provide us with 80% power to detect a minimum 10 percentage point difference in the anticipated impact of the MWH intervention on the primary outcome of facility delivery, a programmatically meaningful difference. We recruited a sample of 240 women for the IDIs (randomly selecting 10% of the household sample) at baseline, and will recruit another 240 at endline.

**Table 3:** Total sample size for evaluation

<i>Evaluation Activity</i>	<i>Intervention Sites</i>	<i>Comparison Sites</i>	<i>Households per Site</i>	<i>X2 Observations (baseline &amp; endline)</i>	<i>Total</i>
<i>Household Survey</i>	20	20	60	2	4800
<i>In-depth Interview*</i>	20	20	6	2	480
<b>TOTAL PARTICIPANTS FOR ALL EVALUATION ACTIVITIES:</b>					<b>4800</b>
<i>*Note that IDIs are a subset of the total household survey population selected for more in-depth information and are therefore NOT factored in as additional human subject participants in the total sample size for this study.</i>					

### Participant recruitment

For the purposes of this evaluation, a household is defined as a group of people who regularly cook together. Inclusion criteria for the household survey are:

- Household with someone who has delivered a baby within the past 12 months
- Respondent must be age 15 or older. If age 15-17, a legal guardian must be available for consent.
- Proxy respondent (if woman deceased) must be over the age of 18
- Resident of the village identified for sampling (>10 km from the facility)

At baseline, conducted in 2016, we employed multi-stage random sampling procedures (Figure 3). We began the first stage of sampling by visiting every village within the catchment area of each study site, informing the local village leader of the purpose of the study and taking the GPS coordinates from the approximate geographical “center” of the village. We input these GPS coordinates into ArcGIS® Online (Esri, Redlands, CA) and used the line creation tool to draw the most direct route along the roads and paths visible on World Imagery basemap between each village center and their associated health facility. We then used this network of roads to determine the distance of each village to the health facility and developed a sampling frame of all villages within each catchment area located more than 10km from the health facility (rounding up from 9.5km). We then randomly selected a sample of 10

1  
2  
3 villages from each catchment area with probability proportional to population size. In the second stage  
4  
5 of sampling, we worked with community volunteers and village leaders to list all households within the  
6  
7 selected villages with a woman that had a delivery in the last year, randomly ordered them, visited each  
8  
9 in that order and confirmed their eligibility for study participation. We continued down the list until the  
10  
11 6<sup>th</sup> eligible household in each village was identified. During the enrollment period, we selected  
12  
13 additional villages and additional households within villages in order to reach our overall goal of 2,400  
14  
15 enrolled households.  
16  
17

18  
19 **INSERT FIGURE 3**  
20  
21  
22

23 The study team and community volunteers introduced the study to potential respondents and  
24  
25 requested permission from the household head or most senior woman in the household to screen for  
26  
27 eligibility. If household eligibility was confirmed, the study team proceeded with the informed voluntary  
28  
29 consent process with the household head or senior woman. Once informed consent was obtained and  
30  
31 documented from the household head or senior woman, the enumerator recorded the geo-location of  
32  
33 the household and commenced the interview or scheduled a later appointment. The household head or  
34  
35 senior woman responded to the first part of the survey for approximately 15 minutes, enumerating all of  
36  
37 the people in the household in a table that captured demographics as well as recent deliveries and  
38  
39 delivery outcomes.  
40  
41  
42

43 Upon completion of the household demographics and enumeration, an eligible woman was  
44  
45 selected to respond to the remainder of the survey. If more than one women in the household had  
46  
47 delivered a baby in the past 12 months, the electronic data capture system randomly selected one  
48  
49 eligible woman to respond to the remainder of the survey. The selected woman was then consented  
50  
51 separately, enrolled in the study, and completed the HHS in a private space where she felt comfortable.  
52  
53  
54 Completion of the HHS took approximately 45-60 minutes.  
55  
56  
57  
58  
59  
60

1  
2  
3 Of the woman respondents, 10% were randomly selected to participate in a 30-minute IDI  
4 immediately following the survey. We will repeat the household-level sampling procedures at endline  
5 (O2 in 2018), selecting a new cross-sectional sample of households and women within the households.  
6  
7 Therefore, the same households will not be followed over time. We will not re-geo-locate villages  
8 unless a new village has formed between baseline and endline.  
9  
10  
11  
12  
13  
14  
15

## 16 **Procedures**

### 17 **Data collection**

18  
19 At baseline, a local team of enumerators literate in the appropriate local language(s) and in  
20 English were trained in qualitative and quantitative research methods and human subjects' protection.  
21 Surveys were designed in SurveyCTO Collect software (Version 2.212; Doherty, Inc.) and captured  
22 electronically using encrypted tablets. The IDIs were digitally captured on audio recorders. Enumerators  
23 explained the tablet system to all respondents and explained the digital audio recorders to those  
24 selected for IDIs. These same methods will be followed at endline.  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 Checks were put in place to guarantee the quality of collected survey data. First, enumerators  
35 participated in an extensive 5-day training. Second, the enumerators were overseen by data collection  
36 team leads with greater experience in data collection fieldwork. Team leads were overseen by a field  
37 supervisor. Team leads and the field supervisors reviewed surveys for quality and completeness nightly.  
38  
39 Third, field supervisors randomly selected a 5% subsample of households to be audited; the auditor  
40 revisited these households and repeated a subset of survey questions that were checked for reliability.  
41  
42 Lastly, data were encrypted, uploaded and transferred nightly to the data analysis team where key  
43 consistency and quality tracking indicators were reviewed in real time. The same quality assurance  
44 methods will be followed at endline.  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Data management**



1  
2  
3 Survey data were captured on tablets and saved to the internal memory. Each evening, a data  
4 team supervisor reviewed the survey and encrypted it so survey data were no longer accessible on the  
5 tablet. The supervisor uploaded encrypted data nightly during the collection period to a secure server  
6 administered by SurveyCTO (Version 2.212; Doherty, Inc.). The evaluation team downloaded the  
7 encrypted data using the SurveyCTO Client software (Version 2.212; Doherty, Inc.), and decrypted the  
8 data using a decryption key generated by the research team.  
9

10  
11 The evaluation team oversaw data entry, management, and storage for qualitative data. All IDs  
12 were translated into English and transcribed verbatim. Digital recorders and paper copies of written  
13 notes were kept in a locked cabinet until transcriptions were checked for quality and accuracy, at which  
14 point audio files were deleted and notes shredded. The electronic transcriptions do not contain  
15 identifying information, only a study ID number linked to their quantitative survey. A separate linking file  
16 for the quantitative and qualitative data is password protected and only accessible to the study team. All  
17 data management methods will be repeated at endline.  
18

### 19 Data analysis

20  
21 The primary independent variable of interest is assignment to the intervention. For the analysis,  
22 we will compare baseline characteristics between the intervention and control groups to assess balance.  
23 We collect data on potential confounders to increase precision, analyze heterogeneity, and, if necessary,  
24 control for any potential imbalance between the groups.  
25

26  
27 All quantitative analyses will be conducted in SAS v9.4 (SAS, Cary, NC). Our quantitative analytic  
28 plan is threefold, yielding descriptive, bivariate and multivariate statistics. First, we will describe the  
29 study sample, stratifying by intervention and control group and testing for differences between the  
30 groups. Second, we will estimate differences between the groups for primary and secondary outcomes.  
31 Categorical variables will be compared between the groups using a chi-squared test when cell sizes are  
32 sufficient or Fisher's exact test when the cell sizes are small; continuous variables will be compared  
33

1  
2  
3 using t-tests if normally distributed or non-parametric Wilcoxon rank sum tests if the distribution is non-  
4  
5 normal. Third, we will fit several regression models to estimate the impact of the intervention on the  
6  
7 primary and secondary outcomes, adjusting for baseline values, assignment matching variables, and any  
8  
9 imbalanced covariates.

11 The primary dependent variable is the probability of facility delivery for most recent birth, based  
12  
13 on self-report by mothers. Secondary outcomes include:

- 16 • Use of MWHs for antenatal, delivery or postnatal services
- 18 • Delivery by cesaerean section
- 21 • Maternal death
- 23 • Neonatal death

25 All qualitative data will be analyzed in Nvivo 10 © software (QSR International Pty Ltd.). We will  
26  
27 conduct a content analysis of the IDI transcripts. Coding themes have been identified *a priori*. Additional  
28  
29 themes will be included as they emerge. We will triangulate findings with the quantitative data to  
30  
31 identify consistencies, inconsistencies or additional themes to be explored. We will use the themes  
32  
33 developed during the baseline analysis to analyze the endline data and identify any new themes as they  
34  
35 emerge.

## 38 **ETHICS AND DISSEMINATION**

### 40 **Ethics approval and consent to participate**

#### 42 **Ethical review boards**

44  
45 Prior to participant enrollment, ethical approvals were obtained from the Boston University Institutional  
46  
47 Review Board (IRB), University of Michigan IRB (for a de-identified dataset only), and the ERES Converge  
48  
49 Research IRB, a private local ethics board in Zambia. We also obtained official approval to proceed with  
50  
51 the study from the Zambia National Health Research Authority, which is responsible for oversight of all  
52  
53 research conducted in the country. Adverse events, unanticipated problems and any protocol changes  
54  
55  
56  
57  
58  
59

1  
2  
3 will be reported to the IRBs and the Zambia National Health Research Authority per their guidelines, and  
4  
5 all investigators will be informed.  
6  
7

### 8 Potential risks and protections 9

10 This study poses minimal risk to study participants and several steps were taken to minimize risk and  
11  
12 burden. To reduce the risk of disclosure of personal or sensitive information enumerators are trained to  
13  
14 stop participants from disclosing information that is too sensitive. Participation may cause some  
15  
16 discomfort from answering certain questions, particularly if the maternal or neonatal health outcomes  
17  
18 were adverse. Enumerators are trained to minimize any potential discomfort or harm to all participants  
19  
20 during all study activities to the greatest extent possible. We minimize any waiting by participants by  
21  
22 scheduling meetings during times convenient to participants and interviews are kept to as short of time  
23  
24 as possible, though breaks are taken or follow-up meetings are scheduled as required. Participants  
25  
26 received small tokens of appreciation valued around \$1-2 (USD) in recognition of their time and  
27  
28 opportunity costs.  
29  
30  
31  
32  
33

### 34 Potential benefits 35

36 There are no direct individual benefits to participating in the study. The evaluation results will  
37  
38 generate evidence on the impact of MWHs on facility delivery for those who live farthest away. Findings  
39  
40 will provide insight for policy makers into how, if found to be effective, MWHs can be part of a broader  
41  
42 strategy to improve maternal and neonatal health outcomes.  
43  
44  
45

### 46 Respondent confidentiality 47

48 Throughout the study, we take care to ensure the confidentiality of data obtained from study  
49  
50 participants. The HHSs and IDIs are carried out in participants' private homes or somewhere the  
51  
52 respondent feels comfortable. We do not proceed with data collection until we can confirm that the  
53  
54 location is acceptable and respondents agree that they feel comfortable discussing study topics.  
55  
56  
57  
58  
59

1  
2  
3 The linking file with identifiable data and basic demographics is stored in a separate file within  
4 the tablet system. Upon completion of data collection, all files are stored on a secure server during data  
5 analysis and report writing. Only BU/RTC investigators have access to identifiable data. All analyses by  
6 study partners are conducted on de-identified datasets per IRB approvals. Analyses are presented in  
7 aggregate format in technical reports to stakeholders and in manuscripts submitted for publication in  
8 scientific journals. Under no circumstances do organizations or individuals have access to the  
9 participant's individual demographic information and potential identifying information (job title, age  
10 range, sex, and village). As explained above, the qualitative data are de-identified, with basic  
11 demographics only.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 Informed consent

25  
26 Prior to any data collection, we discuss the purpose of the study with local leaders so that the  
27 study activities are clearly understood. If a household is eligible, the study team proceeds with the  
28 informed voluntary consent process from the household head or the most senior woman in the  
29 household, introducing themselves, the purpose of the study, and explaining what we are asking of  
30 them in terms of participation, the risks and benefits, the right to withdraw without penalty at any time,  
31 that their information will be kept in a safe location, and that their answers will not be linked to their  
32 names. Participants are informed that the alternative is to not participate in the study. The study team  
33 slowly and clearly asks for consent to participate. If a selected household respondent declines  
34 participation, the next household on the randomly ordered list of eligible households is contacted. If a  
35 household head or senior woman consents to participating, the study team documents written  
36 informed consent and proceeds with the interview. In addition to the household head or a senior  
37 woman, using the same process we also consent the woman selected from within the household to  
38 respond to the survey; in some cases, this may be the same person. A maximum of two individuals are  
39 consented per household.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We anticipate about 15% of the sample in each round to be between 15-17 years of age. In  
4  
5 Zambia, 'emancipated minors' can enroll if they provide assent and their guardian or husband also  
6  
7 provides consent. If a woman's husband is 18 or older, then he can provide informed consent on behalf  
8  
9 of his wife; however, if he is also under 18 years old, then her legal guardian must provide consent. If  
10  
11 under 18, the research team will allow the woman to first determine if she wishes to join the study  
12  
13 (assent is provided) and then obtain consent by the guardian or husband. Thus, the individual's wishes  
14  
15 are protected and she can determine if she wishes to be part of the study.  
16  
17

18  
19 All informed consent or assent/consent is documented with a signature; in the event a  
20  
21 respondent cannot write, a witness signs the informed consent. A participant retains a copy of the  
22  
23 informed consent form. The informed consent and assent processes are always conducted in the  
24  
25 language most preferred by the participant.  
26  
27

## 28 29 Costs and payments

30  
31 For all activities, the participants volunteer only the time taken to complete this survey. There is  
32  
33 no payment provided to participants for any portion of the study.  
34  
35

## 36 37 Dissemination of findings

38  
39 The primary audience for this evaluation is the Government of Zambia, particularly the Ministry  
40  
41 of Health, Ministry of Community Development, and the Ministry of Chiefs and Traditional Affairs, which  
42  
43 will use the results to inform the development of maternal and child health strategies and policies in  
44  
45 Zambia. We have disseminated the baseline findings to key stakeholders internal to Zambia and will  
46  
47 disseminate the full study findings after endline. Many of the findings will likely be of broader interest  
48  
49 throughout the region and globally where maternal mortality is high, resources are low, and access to  
50  
51 facility-based delivery remains an issue. As such, results of this evaluation will be disseminated as widely  
52  
53 as possible through open-access journals, websites, and international conferences.  
54  
55  
56  
57  
58  
59

## Limitations

This study has several limitations. First, half of study clusters could not be randomly assigned to either the intervention or control group due to political constraints. We will analyze the full sample as a quasi-experimental CBA study. Additionally, we will estimate the impact in both the non-randomized and randomized subsamples and assess potential bias introduced by non-random assignment. Second, we limited household eligibility to those living at least 10 km from the health facilities and will not be able to assess impact on women living nearer to facilities. However, remote women are the primary target of the MWH model and stand to benefit the most from the intervention. To manage this limitation, in a separate protocol, we are collecting facility-based data to understand any changes in demographics among those utilizing facilities for delivery. Lastly, because there are two implementing partners, there is a risk that the MWH model will be implemented differently across the sites. To mitigate this risk, we have developed and agreed upon the precise elements of the MWH model based on both partners' formative research [11–13] and will be assessing implementation fidelity using harmonized tools.

## CONCLUSION

Maternity Waiting Homes have the potential to improve access to facility delivery, particularly for women in rural areas living far from health facilities. Despite their widespread use in developing countries, there is currently little evidence of MWH effectiveness. Using community input, we developed a MWH model that responds to community-identified measures of acceptability, safety and comfort. To the best of our knowledge, this is the first large-scale impact evaluation of MWHs. Findings will be triangulated and explained by data from partner-specific process evaluations being implemented concurrently. Findings will generate evidence surrounding the effectiveness of MWHs on improving

1  
2  
3 facility deliveries for remote populations in Zambia and other countries with similar rural and highly  
4  
5 dispersed populations.  
6  
7  
8  
9  
10

## 11 REFERENCES

- 14 1 The United Nations. Goal 3 ... Sustainable Development Knowledge Platform.  
15 <https://sustainabledevelopment.un.org/sdg3> (accessed 2 Feb 2018).
- 16 2 Central Statistical Office (CSO) Zambia, [Ministry of Health (MOH) [Zambia], ICF  
17 International. Zambia Demographic and Health Survey 2013-14. Rockville, Maryland,  
18 USA: 2014.
- 19 3 UN General Assembly. Resolution adopted by the General Assembly on 25 September  
20 2015 70/1. Transforming our world: the 2030 Agenda for Sustainable Development. 2030.  
21 [http://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A\\_RES\\_70\\_1\\_E.pdf](http://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A_RES_70_1_E.pdf) (accessed 17 Jan 2018).
- 22 4 Republic of Zambia Ministry of Health. National Health Strategic Plan 2011 - 2015.  
23 2011;:119.
- 24 5 Republic of Zambia Ministry of Health. Roadmap for Accelerating Reduction of Maternal  
25 , Newborn and Child Mortality , 2013-2016. 2016;:2013–6.
- 26 6 Gabrysch S, Cousens S, Cox J, *et al.* The influence of distance and level of care on  
27 delivery place in rural Zambia: a study of linked national data in a geographic information  
28 system. *PLoS Med* 2011;**8**. doi:10.1371/journal.pmed.1000394
- 29 7 Gabrysch S, Campbell OM, Lawn J, *et al.* Still too far to walk: Literature review of the  
30 determinants of delivery service use. *BMC Pregnancy Childbirth* 2009;**9**:34.  
31 doi:10.1186/1471-2393-9-34
- 32 8 Lori JR, Wadsworth AC, Munro ML, *et al.* Promoting access: The use of maternity  
33 waiting homes to achieve safe motherhood. *Midwifery* 2013;**29**:1095–102.  
34 doi:10.1016/j.midw.2013.07.020
- 35 9 Henry EG, Semrau K, Hamer DH, *et al.* The influence of quality maternity waiting homes  
36 on utilization of facilities for delivery in rural Zambia. *Reprod Health* 2017;**14**:68.  
37 doi:10.1186/s12978-017-0328-z
- 38 10 van Lonkhuijzen L, Stekelenburg J, van Roosmalen J. Maternity waiting facilities for  
39 improving maternal and neonatal outcome in low-resource countries. *Cochrane database*  
40 *Syst Rev* 2012;**10**:CD006759. doi:10.1002/14651858.CD006759.pub3
- 41 11 Lori JR, Munro-Kramer ML, Mdluli EA, *et al.* Developing a community driven  
42 sustainable model of maternity waiting homes for rural Zambia. *Midwifery* 2016;**41**:89–  
43 95. doi:10.1016/j.midw.2016.08.005
- 44 12 Chibuye PS, Bazant ES, Wallon M, *et al.* Experiences with and expectations of maternity  
45 waiting homes in Luapula Province, Zambia: a mixed–methods, cross-sectional study with  
46 women, community groups and stakeholders. *BMC Pregnancy Childbirth* 2018;**18**:42.  
47 doi:10.1186/s12884-017-1649-1
- 48 13 Scott N, Haley C, Gille S. Improving equitable access to safe deliveries in Zambia:  
49 Findings from a formative evaluation. 2014.

- 1  
2  
3 14 Central Statistical Office (CSO) Zambia. 2010 Census of Population and Housing -  
4 Southern Province Analytical Report. Lusaka: 2014.  
5 <http://web0.psa.gov.ph/statistics/census/population-and-housing>  
6  
7 15 Central Statistical Office (CSO) Zambia. 2010 Census of Population and Housing -  
8 Eastern Province Analytical Report. Lusaka: 2014.  
9 [https://www.zamstats.gov.zm/phocadownload/2010\\_Census/2010\\_Census\\_Analytical\\_Reports/Eastern Province Analytical Report - 2010 Census.pdf](https://www.zamstats.gov.zm/phocadownload/2010_Census/2010_Census_Analytical_Reports/Eastern%20Province%20Analytical%20Report%20-%202010%20Census.pdf) (accessed 19 Jan 2018).  
10  
11 16 Central Statistical Office (CSO) Zambia. Zambia 2010 Census of Population and Housing  
12 Population Summary Report. Lusaka: 2012. [http://www.mcaz.gov.zm/wp-](http://www.mcaz.gov.zm/wp-content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf)  
13 [content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf](http://www.mcaz.gov.zm/wp-content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf) (accessed 19  
14 Jan 2018).  
15  
16 17 Hamer DH, Herlihy JM, Musokotwane K, *et al.* Engagement of the Community,  
17 Traditional Leaders, and Public Health System in the Design and Implementation of a  
18 Large Community-Based, Cluster-Randomized Trial of Umbilical Cord Care in Zambia.  
19 *Am J Trop Med Hyg* 2015;**92**:666–72. doi:10.4269/ajtmh.14-0218  
20  
21 18 Semrau KEA, Herlihy J, Grogan C, *et al.* Effectiveness of 4% chlorhexidine umbilical  
22 cord care on neonatal mortality in Southern Province, Zambia (ZamCAT): a cluster-  
23 randomised controlled trial. *Lancet Glob Heal* 2016;**4**:e827–36. doi:10.1016/S2214-  
24 109X(16)30215-7  
25  
26 19 Pagel C, Prost A, Lewycka S, *et al.* Intracluster correlation coefficients and coefficients of  
27 variation for perinatal outcomes from five cluster-randomised controlled trials in low and  
28 middle-income countries: results and methodological implications. *Trials* 2011;**12**:151.  
29 doi:10.1186/1745-6215-12-151  
30  
31

## 32 **AUTHORS STATEMENT**

33  
34  
35 NS led the scientific design, implementation, and was primarily responsible for drafting this  
36 manuscript. JK contributed to the development of the protocol, led the development of the study  
37 sample, coordinated data collection, and contributed to revisions of the manuscript. TV and RB  
38 contributed to the revisions and science of the protocol and data collection instruments. RF  
39 contributed to the development of the protocol, implemented the electronic data capture system,  
40 and contributed to the revisions of this manuscript. TN, GB, CB, and JL provided feedback on the  
41 protocol and reviewed and edited the final manuscript. DH provided scientific support, technical  
42 input into the survey design and critically reviewed and edited the final manuscript. PR helped  
43 conceptualize the scientific design of the study, provided technical input into the survey design,  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 sampling approach, and critically reviewed and edited the final manuscript. All authors read and  
4  
5 approved the final version of the manuscript.  
6  
7  
8

## 9 **FUNDING**

10  
11 This program was developed and is being implemented in collaboration with MSD for Mothers,  
12  
13 MSD's 10-year, \$500 million initiative to help create a world where no woman dies giving life. MSD  
14  
15 for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A. (MRK 1846-06500.COL). The  
16  
17 development of this article was additionally supported in part by the Bill and Melinda Gates  
18  
19 Foundation (OPP1130329) [https://www.gatesfoundation.org/How-We-Work/Quick-](https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/07/OPP1130329)  
20  
21 [Links/Grants-Database/Grants/2015/07/OPP1130329](https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/07/OPP1130329) and The ELMA foundation (ELMA-15-  
22  
23 F0017) <http://www.elmaphilanthropies.org/the-elma-foundation/>. The funders had no role in  
24  
25 study design, data collection and analysis, decision to publish, or preparation of the manuscript.  
26  
27 The content is solely the responsibility of the authors and does not reflect positions or policies of  
28  
29 MSD, the Bill & Melinda Gates Foundation or The ELMA Foundation.  
30  
31  
32  
33

## 34 **CONFLICTS OF INTEREST STATEMENT**

35  
36 The authors declare that they have no competing interests.  
37  
38  
39  
40  
41  
42

## 43 **FIGURE LEGEND**

44  
45 **Figure 1. Minimum Maternity Waiting Home Model in the Maternity Home Alliance for Intervention**  
46  
47 **Sites (n=20).**

48  
49  
50 **Figure 2. Map of the Maternity Home Alliance Intervention and Control Study Sites by Partner**

51  
52 **Figure 3. Multi-stage Random Sampling Strategy for Baseline and Endline**  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Minimum Maternity Waiting Home Model in the Maternity Home Alliance for Intervention Sites (n=20).

101x66mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Map of the Maternity Home Alliance Intervention and Control Study Sites by Partner

173x144mm (300 x 300 DPI)

only




Figure 3. Multi-stage Random Sampling Strategy for Baseline and Endline

97x54mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___1___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___3,clinicaltrials.gov
	2b	All items from the World Health Organization Trial Registration Data Set	1-23 and on clinicaltrials.gov
Protocol version	3	Date and version identifier	___na___
Funding	4	Sources and types of financial, material, and other support	___23___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___1___
	5b	Name and contact information for the trial sponsor	___23___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___23___

1  
2  
3 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint  
4 adjudication committee, data management team, and other individuals or groups overseeing the trial, if  
5 applicable (see Item 21a for data monitoring committee) \_\_\_\_\_ na \_\_\_\_\_  
6  
7  
8  
9

## 10 Introduction

11  
12  
13 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant  
14 rationale studies (published and unpublished) examining benefits and harms for each intervention \_\_\_\_\_ 5,6 \_\_\_\_\_  
15  
16 6b Explanation for choice of comparators \_\_\_\_\_ 8 \_\_\_\_\_  
17 Objectives 7 Specific objectives or hypotheses \_\_\_\_\_ 5,6 \_\_\_\_\_  
18  
19 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),  
20 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_\_\_\_ 8 \_\_\_\_\_  
21  
22

## 23 Methods: Participants, interventions, and outcomes

24  
25 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will  
26 be collected. Reference to where list of study sites can be obtained \_\_\_\_\_ 7 \_\_\_\_\_  
27  
28 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and  
29 individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_\_\_\_ 8,9,12 \_\_\_\_\_  
30  
31 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be  
32 administered \_\_\_\_\_ 6 \_\_\_\_\_  
33  
34 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose  
35 change in response to harms, participant request, or improving/worsening disease) \_\_\_\_\_ na \_\_\_\_\_  
36  
37 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence  
38 (eg, drug tablet return, laboratory tests) \_\_\_\_\_ na \_\_\_\_\_  
39  
40 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_\_\_\_ na \_\_\_\_\_  
41  
42  
43

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	____ 6,7,16 ____
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	____ 11 ____
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	____ 11 ____
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	____ 13 ____

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	____ 9, 12, 13, ____
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	____ na ____
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	____ na ____
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	____ na ____
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	____ na ____

**Methods: Data collection, management, and analysis**

1				
2				
3	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	_____6-14_____
4	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
5			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
6			Reference to where data collection forms can be found, if not in the protocol	
7				
8		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	_____na_____
9			collected for participants who discontinue or deviate from intervention protocols	
10				
11	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality	_____14, 15_____
12			(eg, double data entry; range checks for data values). Reference to where details of data management	
13			procedures can be found, if not in the protocol	
14				
15	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	_____15, 16_____
16			statistical analysis plan can be found, if not in the protocol	
17				
18		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____16_____
19				
20		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any	
21			statistical methods to handle missing data (eg, multiple imputation)	_____na_____
22				
23				
24	<b>Methods: Monitoring</b>			
25	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of	_____na_____
26			whether it is independent from the sponsor and competing interests; and reference to where further details	
27			about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not	
28			needed	
29				
30				
31		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim	_____na_____
32			results and make the final decision to terminate the trial	
33				
34	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse	_____16, 17_____
35			events and other unintended effects of trial interventions or trial conduct	
36				
37	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent	_____na_____
38			from investigators and the sponsor	
39				

**Ethics and dissemination**



1  
2  
3 Research ethics 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval \_\_\_\_\_16\_\_\_\_\_

4 approval

5  
6 Protocol 25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, \_\_\_\_\_16, 17\_\_\_\_\_

7 amendments analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, \_\_\_\_\_

8 regulators)

9  
10 Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and \_\_\_\_\_18, 19\_\_\_\_\_

11 how (see Item 32)

12  
13 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary \_\_\_\_\_na\_\_\_\_\_

14 studies, if applicable

15  
16 Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained \_\_\_\_\_17, 18\_\_\_\_\_

17 in order to protect confidentiality before, during, and after the trial

18  
19 Declaration of 28 Financial and other competing interests for principal investigators for the overall trial and each study site \_\_\_\_\_23\_\_\_\_\_

20 interests

21  
22 Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that \_\_\_\_\_18\_\_\_\_\_

23 limit such access for investigators

24  
25 Ancillary and post- 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial \_\_\_\_\_na\_\_\_\_\_

26 trial care participation

27  
28 Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, \_\_\_\_\_19\_\_\_\_\_

29 the public, and other relevant groups (eg, via publication, reporting in results databases, or other data \_\_\_\_\_

30 sharing arrangements), including any publication restrictions

31  
32 31b Authorship eligibility guidelines and any intended use of professional writers \_\_\_\_\_22, 23\_\_\_\_\_

33  
34 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code \_\_\_\_\_na\_\_\_\_\_

35  
36 **Appendices**

37  
38 Informed consent 32 Model consent form and other related documentation given to participants and authorised surrogates \_\_\_\_\_Can be provided

39 materials upon request\_\_\_\_\_

40  
41  
42  
43  
44  
45  
46  
47

1  
2  
3 Biological 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular \_\_\_\_\_na\_\_\_\_\_  
4 specimens analysis in the current trial and for future use in ancillary studies, if applicable

---

5  
6 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
7 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
8 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

# BMJ Open

## Impact of maternity waiting homes on facility delivery among remote households in Zambia: protocol for a quasi-experimental, mixed-methods study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022224.R1
Article Type:	Protocol
Date Submitted by the Author:	31-May-2018
Complete List of Authors:	Scott, Nancy; Boston University School of Public Health, Global Health Kaiser, Jeanette; Boston University School of Public Health, Global Health Vian, Taryn; Boston University School of Public Health, Global Health Bonawitz, Rachael; Boston University School of Public Health, Global Health; Boston University School of Medicine, Pediatrics Fong, Rachel; Boston University School of Public Health, Global Health Ngoma, Thandiwe; Right to Care Zambia Biemba, Godfrey; National Health Research Authority, Pediatric Centre of Excellence Boyd, Carol; University of Michigan School of Nursing, Health Behavior & Biological Sciences Lori, Jody; University of Michigan School of Nursing, Center for Global Affairs & PAHO/WHO Collaborating Center Hamer, D.; Boston University, Rockers, Peter; Boston University, Department of Global Health
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Research methods, Global health, Qualitative research
Keywords:	maternity waiting home, maternal health, skilled birth attendance, mixed methods, impact evaluation, Zambia

SCHOLARONE™  
Manuscripts

**Title:** *Impact of maternity waiting homes on facility delivery among remote households in Zambia: protocol for a quasi-experimental, mixed-methods study*

**Authors:**

Name	Institutional Address	Email Address
Nancy Scott	Department of Global Health, Boston University School of Public Health, Boston, USA 801 Massachusetts Ave, Boston, MA 02118	<a href="mailto:nscott@bu.edu">nscott@bu.edu</a> (corresponding) Tel: +1-617-414-1278
Jeanette Kaiser	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:jkaiser@bu.edu">jkaiser@bu.edu</a>
Taryn Vian	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:tvian@bu.edu">tvian@bu.edu</a>
Rachael Bonawitz	Department of Global Health, Boston University School of Public Health Boston, MA USA Department of Pediatrics, Boston University School of Medicine Boston, MA USA	<a href="mailto:rebonawi@bu.edu">rebonawi@bu.edu</a>
Rachel Fong	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:rmfong@bu.edu">rmfong@bu.edu</a>
Thandiwe Ngoma	Right to Care-Zambia Lusaka, Zambia	<a href="mailto:ngoma.thandiwe@gmail.com">ngoma.thandiwe@gmail.com</a>
Godfrey Biemba	National Health Research Authority, Pediatric Centre of Excellence Lusaka, Zambia	<a href="mailto:gbiemba@gmail.com">gbiemba@gmail.com</a>
Carol J. Boyd	Department of Health Behavior & Biological Sciences School of Nursing, University of Michigan Ann Arbor, MI USA	<a href="mailto:caroboyd@med.umich.edu">caroboyd@med.umich.edu</a>
Jody R. Lori	Center for Global Affairs & PAHO/WHO Collaborating Center School of Nursing, University of Michigan Ann Arbor, MI USA	<a href="mailto:jrlori@umich.edu">jrlori@umich.edu</a>
Davidson H. Hamer	Department of Global Health, Boston University School of Public Health Boston, MA USA  Section of Infectious Diseases, Department of Medicine, Boston Medical Center Boston, MA USA	<a href="mailto:dhamer@bu.edu">dhamer@bu.edu</a>
Peter C. Rockers	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:prockers@bu.edu">prockers@bu.edu</a>

**Word count:** 4,200 (excluding title page, abstract, references, figures and tables)

## List of Acronyms

Africare/UM	Africare/University of Michigan
ANC	Antenatal care
BEmONC	Basic emergency obstetric and newborn care
BU/RTC	Boston University/Right to Care Zambia
CBA	Controlled before-and-after
CEmONC	Comprehensive emergency obstetric and newborn care
GRZ	Government of the Republic of Zambia
HHS	Household survey
IDI	In-depth interview
IRB	Institutional review board
MHA	Maternity Homes Alliance
MMR	Maternal mortality ratio
MSD	Merck Sharp & Dohme
MWH	Maternity Waiting Home
PNC	Postnatal care
SDG	Sustainable Development Goals

## ABSTRACT

**Introduction:** Maternity waiting homes (MWHs) aim to improve access to facility delivery in rural areas. However, there is limited rigorous evidence of their effectiveness. Using formative research, we developed a MWH intervention model with three components: infrastructure, management, and linkage to services. This protocol describes a study to measure the impact of the MWH model on facility delivery among women living farthest ( $\geq 10$ km) from their designated health facility in rural Zambia. This study will generate key new evidence to inform decision making for MWH policy in Zambia and globally.

**Methods and analysis:** We are conducting a mixed-methods quasi-experimental impact evaluation of the MWH model using a controlled before-and-after design in 40 health facility clusters. Clusters were assigned to the intervention or control group using two methods: 20 clusters were randomly assigned using a matched-pair design; the other 20 were assigned without randomization due to local political constraints. Overall, 20 study clusters receive the MWH model intervention while 20 control clusters continue to implement the 'standard of care' for waiting mothers. We recruit a repeated cross-section of 2,400 randomly sampled recently-delivered women at baseline (2016) and endline (2018); all participants are administered a household survey and a 10% subsample also participates in an in-depth interview. We will calculate descriptive statistics and adjusted odds ratios; qualitative data will be analyzed using content analysis. The primary outcome is the probability of delivery at a health facility; secondary outcomes include utilization of MWHs and maternal and neonatal health outcomes.

**Ethics and dissemination:** Ethical approvals were obtained from the Boston University Institutional Review Board (IRB), University of Michigan IRB (de-identified data only), and the ERES Converge IRB in Zambia. Written informed consent is obtained prior to data collection. Results will be disseminated to key stakeholders in Zambia, then through open-access journals, websites, and international conferences.

**Trial Registration:** ClinicalTrials.gov Identifier: NCT02620436

**Keywords:** maternity waiting home, maternal health, facility delivery, mixed methods, impact evaluation, Zambia

## ARTICLE SUMMARY

### Strengths and limitations of this study

This study has several strengths and limitations, including:

- To the best of our knowledge, this is the first large-scale impact evaluation of MWHs, employing a rigorous controlled before-and-after, quasi-experimental design and using mixed-methods.
- For generalizability, a representative sample of recently-delivered women living most remotely is selected using a multi-stage, random sampling strategy for both the quantitative household surveys and the qualitative in-depth interviews.
- Half of study clusters could not be randomly assigned to either the intervention or control group due to political constraints, resulting in quasi-experimental study design.
- Because remote women stand to benefit the most from the MWH model, eligibility is limited to those living at least 10km from the health facilities; findings will therefore not be able to assess impact of the intervention on women living nearer to facilities.
- In companion protocols, implementation fidelity of the core elements of the MWH model is assessed by each partner using harmonized tools.

## INTRODUCTION

The Sustainable Development Goals (SDGs) include a target of reducing the global maternal mortality ratio (MMR) to less than 70 deaths per 100,000 live births by 2030.[1] Zambia's MMR is currently 398 deaths per 100,000 live births, well above the SDG target.[2,3] Skilled care at every birth, one of the two SDG indicators for MMR, is recommended. What remains unanswered is how to best facilitate access to intrapartum and postpartum care, particularly in rural and remote areas where distance and poor transportation severely restrict access to care. The Government of the Republic of Zambia (GRZ) is committed to improving maternal health and encourages facility-based delivery for all women,[4,5] though accessing facilities for birth is challenging for women living in remote areas.[6–9]

Maternity waiting homes (MWHs) are lodgings located near health facilities where mothers who are close to term can await delivery. These homes are meant to provide pregnant women with the option of planning ahead and traveling to health facilities well before labor begins. MWHs may be a promising strategy to improve access to facilities for delivery, the evidence is mixed. While some evidence suggests they are associated with higher rates of facility delivery and improved maternal health outcomes,[10–20] a Cochrane review found that there are no randomized or quasi-randomized trials assessing the effectiveness of MWHs in low-resource settings.[21] Additionally, it is unclear if MWHs can increase access to facility delivery among women living most remotely.[19,22] Rigorous evidence on the impact of MWHs on facility deliveries is needed.

This protocol describes a study being conducted by the Maternity Homes Alliance (MHA), a partnership between the GRZ, Boston University and Right to Care Zambia, formerly the Zambian Center for Applied Health Research and Development (BU/RTC), Africare and the University of Michigan (Africare/UM), and funded by Merck Sharp and Dohme (MSD) for Mothers, the Bill & Melinda Gates Foundation, and The ELMA Foundation. The MHA hypothesizes that MWHs can remove the distance



1  
2  
3 barrier and increase access to facility-based delivery. In this study, we test the impact of MWHs on  
4 facility delivery among women living at least 10km from health facilities in rural Zambia.  
5  
6

7  
8 MWHs have the potential to improve access to facility delivery, particularly for women in rural  
9 areas living far from health facilities. Despite their widespread use in developing countries, there is  
10 currently little evidence of MWH effectiveness. Using community input, we developed a MWH model  
11 and are evaluating it for impact. To the best of our knowledge, this is the first large-scale impact  
12 evaluation of MWHs. Findings will generate evidence surrounding the effectiveness of MWHs on  
13 improving facility deliveries for remote populations in Zambia and other countries with similar rural and  
14 highly dispersed populations.  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **Intervention**

25  
26  
27 While the government of Zambia supports the use of MWHs as a strategic method to increase  
28 access to skilled birth attendance [5,23] and MWHs have existed in Zambia for decades, there is no  
29 specific policy or plan for the scale-up of MWHs and their general quality remains low.[13,24–26] MWHs  
30 have been largely constructed through community initiatives or international donors, with limited  
31 support for their long-term maintenance.[24–26] Formative evaluations conducted previously by  
32 members of the study team in the current study setting showed that MWHs could be an acceptable and  
33 feasible option to improve access to facilities for delivery.[24–26] Informed by these findings, the core  
34 MWH model was designed to be responsive to community expectations, community-defined standards  
35 of acceptability and their perceptions of quality including safety, comfort, management and services  
36 offered (Figure 1). In direct response to the formative data, the model includes the following:  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

- 50 • **Infrastructure, Supplies and Equipment:** The core MWH model has concrete walls and floors,  
51 roofs that do not leak, latrines, a private bathing space, water within a reasonable distance, a  
52 covered cooking space, and storage space. For safety, the core MWH model has lockable doors,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 windows, cupboards, and lighting. Amenities include beds, mattresses, bedding, mosquito nets,  
4  
5 and cooking utensils.  
6  
7

- 8 • **Policies, Management and Finances:** The core MWH model is community-owned and operated,  
9  
10 as requested by the Ministry of Health. The policies, management, and financial structures are  
11  
12 adaptable to site-specific needs and preferences, though all have a formalized governance and  
13  
14 management structure with community, government and health facility representation. Each  
15  
16 also has a management unit responsible for daily operations including registering and orienting  
17  
18 women, record keeping and maintenance.  
19  
20
- 21 • **Linkages & Services:** Each core MWH model is situated close to the health facility to ensure  
22  
23 timely access to clinical care when a woman's labor begins. A health facility staff provides daily  
24  
25 check-ins with waiting women, though clinical care visits continue to be conducted at the health  
26  
27 facility, not in the MWH. Women staying at the MWH have the opportunity to participate in  
28  
29 maternal and child education courses offered by the health facility staff or community health  
30  
31 workers.  
32  
33  
34  
35  
36  
37  
38

39 **INSERT FIGURE 1**  
40  
41  
42  
43

44 The core MWH model is promoted in the community through several mechanisms. First, health  
45  
46 facility staff promote the MWH at all ANC visits. Over 95% of women attend at least the first ANC visit ,  
47  
48 so most women are exposed at the health facility.[2] Second, Safe Motherhood Action Group members  
49  
50 promote the use of MWHs during their routine outreach activities. Lastly, the traditional leadership  
51  
52 (chiefs and headmen) actively promotes the use of MWHs at their community meetings. The MWH  
53  
54 model targets all pregnant women within 1-2 weeks of their estimated delivery date resident within the  
55  
56  
57  
58  
59  
60

1  
2  
3 catchment area, prioritizing those women living farthest away (i.e. > 10 km from the health facility). The  
4  
5 20 MWHs opened in phases between mid-2016 and mid-2017.  
6  
7

## 8 **METHODS**

9

### 10 **Evaluation questions**

11

12 The primary research question is:

- 13
- 14 1. What is the impact of the MWH model on the probability of facility delivery among mothers  
15  
16 living more than 10 km from the health facility?  
17  
18

19 Secondary questions include:

- 20
- 21 1. Do awareness and perceptions of health facility-associated safe delivery and health facility  
22  
23 delivery intention among pregnant women living in communities located more than 10 km from  
24  
25 the health facility change over time in MWH model sites?  
26  
27
  - 28 2. How do awareness and perceptions of MWHs by communities located more than 10 km from  
29  
30 the health facility change over the period of this study?  
31  
32
  - 33 3. What financial impact does the use of the MWH model have on the families of women who  
34  
35 utilize it?  
36  
37
  - 38 4. How does the perception of quality and acceptability differ between MWH model sites and  
39  
40 comparison sites?  
41  
42
  - 43 5. What is the impact of the MWH model on maternal and neonatal health outcomes among those  
44  
45 living more than 10 km from the facility?  
46  
47

### 48 **Study setting**

49

50 This study began in March 2016 and will be completed in December 2018. The intervention and  
51  
52 comparison sites are located in the primarily rural Zambian districts of Choma, Kalomo and Pemba  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 Districts of Southern Province; Nyimba and Lundazi Districts of Eastern Province; and Mansa and  
4  
5 Chembe Districts of Luapula Province (Figure 2).  
6

#### 7 8 **INSERT FIGURE 2** 9

10  
11 Choma district has a population of 247,860 and a population density of 34/km<sup>2</sup>, with 68.7% of its  
12  
13 population being rural. Kalomo district has a population of 258,570 and a population density of  
14  
15 17.2/km<sup>2</sup>, with 91.8 percent of its population being rural.[27] Nyimba district has a population of 85,025  
16  
17 and a population density of 8.1/km<sup>2</sup>, with 91 percent of its population being rural. Lundazi district has a  
18  
19 population of 323,870 and a population density of 23/km<sup>2</sup>, with 95.1 percent of its population being  
20  
21 rural.[28] Mansa district has a population of 228,392 and a population density of 23.1/km<sup>2</sup>, with 61.9  
22  
23 percent of its population being rural.[29]  
24  
25  
26  
27  
28  
29

#### 30 31 **Study design** 32

33 This study employs a quasi-experimental controlled before-and-after (CBA) design with a total of  
34  
35 40 study clusters, 20 intervention and 20 control clusters.. Clusters consist of health facilities and their  
36  
37 catchment households. Intervention clusters are receiving the MWH model, inclusive of newly  
38  
39 constructed homes with the elements from the three domains: (1) infrastructure, equipment and  
40  
41 supplies; 2) policies, management and finances; and 3) linkages and services detailed in the intervention  
42  
43 section of the protocol. Control clusters are implementing the 'standard of care' for waiting mothers in  
44  
45 Zambia. Because no national policy exists, the standard of care is facility-driven and varies widely. Some  
46  
47 standard-of-care facilities have no designated space for a mother to wait; others have no MWH but  
48  
49 provide a designated space for waiting mothers within the clinic; and a small number have an existing  
50  
51 MWH-like structure but with highly variable quality.[13]  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Eligibility criteria of study clusters

Because the intervention aims to generate demand for health facility delivery, it is critical that facilities are capable of managing basic emergency obstetric and neonatal complications (BEmONC). Because of inconsistencies in available secondary data sources across the different districts, we established supplemental criteria that could be drawn from the available sources.[30,31] Clusters were eligible for inclusion in the study if the health facility was located  $\leq 2$  hours driving time to a comprehensive emergency obstetric and neonatal care (CEmONC) capable referral facility, performed a minimum of 150 deliveries per year AND met at least one of two sets of conditions below:

#### Eligibility condition set 1:

- i. Facility is able to provide at least 5 of 7 BEmONC signal functions based on 2015 data;

#### Eligibility condition set 2:

- i. Facility has at least one skilled birth attendant on staff;
- ii. Facility routinely provide active management of third stage of labor;
- iii. Facility has had no stock outs of oxytocin in the last 12 months;
- iv. Facility has had no stock outs of magnesium sulfate in the last 12 months;

### Selection and assignment of study clusters to study arm

There are a total of 40 clusters (20 intervention, 20 comparison) in this study (Table 1). Each implementing partner used different methods to select and assign clusters to study arms. One partner had a total of 36 eligible health facilities that were located  $\leq 2$  hours driving time to a referral facility and performed a minimum of 150 deliveries. Of those, 22 (61%) met one of the two eligibility conditions. This partner selected the 20 farthest away from referral, created 10 pairs matched on annual delivery

volume and distance, then randomized matched pairs to intervention or control, using the RAND function in Microsoft Excel®.

**Table 1:** Quasi-experimental study design to evaluate the impact of MWHs

Randomized subsample (n=20 clusters)	Non-randomized subsample (n=20 clusters)	Non-randomized full sample (n=40 clusters)
R O1 X O2	NR O1 X O2	NR O1 X O2
R O1 _ O2	NR O1 _ O2	NR O1 _ O2

*X = Minimum Core Maternity Home (see above)*

*O = Observations at baseline (O1, in 2016) and endline (O2, in 2018) at intervention (X) and comparison ( \_ ) sites.*

*R = cluster randomized; NR = not randomized*

The other partner had a total of 29 eligible health facilities that were located  $\leq 2$  hours driving time to a referral facility and performed a minimum of 150 deliveries. Of those, 22 (76%) met one of the two sets of eligibility conditions. This partner was unable to randomly allocate sites to a study arm due to local political constraints, as the Ministry of Health feared community fatigue due to the large number of organizations implementing projects and conducting research. As such, the partner worked with the Ministry of Health to identify 10 intervention sites. From the remaining eligible, they excluded those with an existing functional MWH, then selected comparison sites matched on annual delivery volume and distance to a referral hospital.

### Data sources

Population data are being collected from two main sources: household surveys (HHS) and in-depth interviews (IDIs). Baseline data collection occurred in early 2016 prior to the implementation of the MWH model in intervention clusters; endline data collection will occur in late 2018, after an 18 month intervention period. The HHS is administered to a sample of 2,400 recently delivered women (eligibility criteria described below) residing in intervention and control clusters. In the case of maternal death, the household head or senior woman was interviewed as a proxy participant.

The HHS captures information on the domains and data fields seen in Table 2. The HHS was pretested among a sample of 50 participants representing all the major local languages. At baseline, only small adjustments were made in response to the pre-test, primarily changing formal translations into the vernacular.

**Table 2.** Summary table of data fields collected from the household survey

<b>Household Panel:</b>	<ul style="list-style-type: none"> <li>• Geo-coordinates of household/distance from nearest health facility</li> <li>• Age and sex of household members</li> <li>• Education level of household members</li> <li>• Recent pregnancy/delivery of household members</li> </ul>
<b>Individual Demographics and Household Characteristics</b>	<ul style="list-style-type: none"> <li>• Number of pregnancies</li> <li>• Outcome of pregnancies</li> <li>• Number of living/deceased children</li> <li>• Characteristics of living quarters (e.g., roof type, floor type, cooking fuel type)</li> <li>• Access to and quality of water</li> <li>• Household wealth indicators and assets</li> </ul>
<b>Last Pregnancy</b>	<ul style="list-style-type: none"> <li>• Antenatal care services utilized</li> <li>• HIV testing               <ul style="list-style-type: none"> <li>○ Status</li> <li>○ PMTCT*</li> </ul> </li> <li>• Perceived satisfaction with antenatal care</li> </ul>
<b>Last Delivery</b>	<ul style="list-style-type: none"> <li>• Location of last delivery               <ul style="list-style-type: none"> <li>○ Decision-maker in location of delivery</li> <li>○ Mode of transportation</li> </ul> </li> <li>• Referral and bypassing</li> <li>• Receipt of CEmONC services (C-section, blood transfusion, IV antibiotics)</li> <li>• Perceived quality/satisfaction with delivery services</li> <li>• Maternal and neonatal vital status</li> </ul>
<b>Use of MWH</b>	<ul style="list-style-type: none"> <li>• Knowledge of MWH</li> <li>• Source of knowledge of MWH</li> <li>• Nearest MWH to home</li> <li>• Use of MWH before/after last delivery               <ul style="list-style-type: none"> <li>○ Cost of using mother's shelter</li> <li>○ Perceived quality of mother's shelter (safety, comfort, management and services)</li> <li>○ Satisfaction with mother's shelter</li> </ul> </li> <li>• Prior use of MWH</li> <li>• Intended future use of MWH</li> </ul>
<b>Cost of Delivery and Delivery</b>	<ul style="list-style-type: none"> <li>• Planned or intended location for delivery</li> </ul>

<b>Planning</b>	<ul style="list-style-type: none"> <li>○ Adherence to planned or intended location for delivery</li> <li>● Barriers to birth plan adherence</li> <li>● Savings for last delivery</li> <li>● Cost of last delivery (broken down by expense)</li> </ul>
<b>Postnatal Care (PNC) and infant health</b>	<ul style="list-style-type: none"> <li>● Time to first maternal and newborn post-natal visit after delivery</li> <li>● Perceived quality of post-natal services received</li> <li>● Breastfeeding practices</li> <li>● Supplementary feeding practices</li> <li>● Newborn vaccination status</li> <li>● PMTCT/ART<sup>++</sup> for newborn</li> <li>● Interactions between the parent and the child</li> <li>● Maternal depression assessment</li> <li>● Health seeking behavior for child's last illness</li> </ul>
<b>Health Care Knowledge and Beliefs</b>	<ul style="list-style-type: none"> <li>● Use of contraceptives for family planning</li> <li>● Primary barriers to accessing health care</li> <li>○ Primary barriers to accessing skilled delivery services</li> </ul>

\* PMTCT = Prevention of mother-to-child transmission of HIV; <sup>++</sup>ART = Antiretroviral therapy

In-depth interviews are conducted among a subsample of 240 HHS participants in order to gain a deeper understanding of community awareness, perceptions and experiences. Because the seven districts are spread out and culturally different, we wanted to ensure we reached saturation or predictability in each district to better explore context with the qualitative data.[32] Consequently, we planned to conduct a large number of in-depth interviews to make sure there was sufficient coverage of different populations to provide insight into the quantitative survey findings. IDI content builds upon themes captured in the HHS and includes perceptions of labor and delivery practices, barriers to accessing care, knowledge and awareness of MWHs, sources of knowledge of MWH, perceptions of the quality of maternity homes (safety, comfort, management and services), perceptions of MWH ownership, perceptions of health facility, and expenses incurred for last delivery.

The population-based approach captures the experiences of those who utilized the facility in their catchment, other facilities, and those who did not access a facility for delivery, allowing us to more accurately estimate the impact of the MWH model intervention among women living farthest from the health facility in an intention-to-treat analysis.



### Sampling strategy and sample size

To estimate the impact of the MWH model based on an intention-to-treat analysis, we aim to select a representative sample of women in our sample frame who delivered a baby in the past 12 months, irrespective of her place of delivery or her use of a MWH. With this strategy, we will also be able to explore the relationship between use of the MWH and location of delivery. As such, we are recruiting a repeated cross-section of 2,400 households at each round for the survey (approximately 60 households per cluster): 1,200 from both intervention and control sites at both baseline (completed in 2016) and endline (planned for 2018), for a total study sample of 4,800 households (Table 3).

**Table 3:** Total sample size for evaluation

<i>Evaluation Activity</i>	<i>Intervention Sites</i>	<i>Comparison Sites</i>	<i>Households per Site</i>	<i>X2 Observations (baseline &amp; endline)</i>	<i>Total</i>
<i>Household Survey</i>	20	20	60	2	4800
<i>In-depth Interview*</i>	20	20	6	2	480
<b>TOTAL PARTICIPANTS FOR ALL EVALUATION ACTIVITIES:</b>					<b>4800</b>
<i>*Note that IDIs are a subset of the total household survey population selected for more in-depth information and are therefore NOT factored in as additional human subject participants in the total sample size for this study.</i>					

After accounting for the clustered sampling design (ICC estimated at 0.04 based on previous work [33–35]), and assuming an alpha of .05, this sample will provide us with 80% power to detect a minimum 10 percentage point difference in the anticipated impact of the MWH intervention on the primary outcome of facility delivery, a programmatically meaningful difference. We recruited a sample of 240 women for the IDIs (randomly selecting 10% of the household sample) at baseline, and will recruit another 240 at endline.

### Participant recruitment

For the purposes of this evaluation, a household is defined as a group of people who regularly cook together. Inclusion criteria for the household survey are:

- 1
- 2
- 3 • Household with someone who has delivered a baby within the past 12 months,
- 4
- 5 irrespective of maternal or infant vital status
- 6
- 7
- 8 • Participant must be age 15 or older. If age 15-17, a legal guardian must be available for
- 9
- 10 consent.
- 11
- 12 • Proxy participant (if woman deceased) must be over the age of 18
- 13
- 14 • Resident of the village identified for sampling ( $\geq 10$  km from the facility)
- 15
- 16

17 To select a sample representative of women living at least 10km from our health facility, we  
18 employ multi-stage random sampling procedures (Figure 3). We begin the first stage of sampling by  
19 visiting every village within the catchment area of each study site, informing the local village leader of  
20 the purpose of the study and taking the GPS coordinates from the approximate geographical “center” of  
21 the village. We input these GPS coordinates into ArcGIS® Online (Esri, Redlands, CA) and use the line  
22 creation tool to draw the most direct route along the roads and paths visible on the World Imagery  
23 basemap between each village center and their associated health facility. We then use this network of  
24 roads to calculate the distance of each village to the health facility and develop a sampling frame of all  
25 villages within each catchment area located more than 10km from the health facility (rounding up from  
26 9.5km). We then randomly select a sample of 10 villages from each catchment area with probability  
27 proportional to population size. We list every eligible village within a catchment area in Microsoft Excel®  
28 along with the total population of the village. We assign a series of numbers to each village,  
29 corresponding to the population size (i.e. if village 1 had 30 people, 1-30; village 2 had 20 inhabitants,  
30 31-50), and use the random number generator function to select the villages in each catchment area.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Second, we work with community volunteers and village leaders to list all households within the  
49 selected villages that have a woman who had a delivery in the last year. We randomly order them by  
50 rolling a dice twice, first for a random start and then for a random skip until all households are ordered.  
51 We visit each household in that order and confirm their eligibility for study participation. We continue  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 down the list until six eligible household in each village are identified. We select additional villages and  
4 additional households if necessary to reach our sample of 2,400 households per round. This process  
5 assumes that the health facility staff are able to accurately and completely identify all villages within  
6 their catchment area.  
7  
8  
9  
10

### 11 12 13 **INSERT FIGURE 3** 14 15

16  
17  
18 The study team and community volunteers introduce the study to potential participants and  
19 request permission from the household head or most senior woman in the household to screen for  
20 eligibility. If household eligibility is confirmed, the study team proceeds with the informed voluntary  
21 consent process with the household head or senior woman. Once informed consent is obtained and  
22 documented from the household head or senior woman, the enumerator records the geo-location of  
23 the household and commences the interview or schedules a later appointment. The household head or  
24 senior woman responds to the first part of the survey for approximately 15 minutes, enumerating all of  
25 the people in the household in a table that captures demographics as well as recent deliveries and  
26 delivery outcomes.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Upon completion of the household demographics and enumeration, an eligible woman was  
39 selected to respond to the remainder of the survey. If more than one women in the household had  
40 delivered a baby in the past 12 months, the electronic data capture system is programmed to randomly  
41 selecte one eligible woman to respond to the remainder of the survey. The selected woman then  
42 consents separately, enrolls in the study, and completes the HHS in a private space where she feels  
43 comfortable. Completion of the HHS takes approximately 45 minutes.  
44  
45  
46  
47  
48  
49  
50

51 Of the woman participants, 10% are randomly selected to participate in a 30-minute IDI  
52 immediately following the survey. IDI participants can take a short break after ther HHS, or reschedule if  
53 more convenient. The household-level sampling procedures described here have been conducted at  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 baseline (2016) and will be conducted at endline (2018) with a new cross-sectional sample of  
4  
5 households and women within the households. Therefore, the same households are not followed over  
6  
7 time.  
8  
9

## 10 11 12 **Patient and public involvement** 13

14  
15 The development of the research question and outcome measures were informed by key  
16  
17 stakeholders and patients' experience and preferences derived from free list responses, key informant  
18  
19 interviews, and focus group discussions conducted during the formative evaluation [24–26]. Input from  
20  
21 key stakeholders and community members helped to ensure that the design of the intervention would  
22  
23 be responsive to community standards of acceptability of factors such as safety and comfort, and a  
24  
25 feasible option to increase facility deliveries. Patients were not involved in studydesign, recruitment,  
26  
27 and or conduct of the trial. Given the nature of the intervention, there was limited potential burden on  
28  
29 patients and therefore, the burden of the randomized controlled trial was not assessed by the patients.  
30  
31  
32

33 The primary audience for this evaluation is the Government of Zambia, particularly the Ministry  
34  
35 of Health, Ministry of Community Development, and the Ministry of Chiefs and Traditional Affairs, which  
36  
37 will use the results to inform the development of maternal and child health strategies and policies in  
38  
39 Zambia. We have disseminated the baseline findings to key stakeholders internal to Zambia and will  
40  
41 disseminate the full study findings after endline. Many of the findings will likely be of broader interest  
42  
43 throughout the region and globally where maternal mortality is high, resources are low, and access to  
44  
45 facility-based delivery remains an issue. As such, results of this evaluation will be disseminated as widely  
46  
47 as possible through open-access journals, websites, and international conferences.  
48  
49  
50

## 51 52 53 **Procedures** 54

### 55 56 **Data collection** 57 58 59 60

1  
2  
3 At baseline and endline, a local team of enumerators literate in the appropriate local  
4 language(s) and in English are trained in qualitative and quantitative research methods and human  
5 subjects' protection. Surveys are designed in SurveyCTO Collect software (Version 2.212; Doherty, Inc.)  
6 and are captured electronically using encrypted tablets. The IDIs are digitally captured on audio  
7 recorders. Enumerators explain the tablet system to all participants and explain the digital audio  
8 recorders to those selected for IDIs.  
9

10  
11  
12 Several checks assure the quality of collected survey data. First, enumerators participate in an  
13 extensive 5-day training. Second, the enumerators are overseen by data collection team leads with  
14 greater experience in data collection fieldwork. Team leads are overseen by a field supervisor. Team  
15 leads and the field supervisors review surveys for accuracy and completeness nightly. Third, field  
16 supervisors randomly select a 5% subsample of households to be audited; the auditor revisits these  
17 households and repeats a subset of survey questions that are checked for reliability. Fourth, the field  
18 supervisors conduct a short nightly debrief with the data leads who each oversee three other data  
19 collectors and are responsible for conducting the IDIs. Debriefs cover the following topics: field  
20 challenges, sampling, total surveys conducted, and IDIs. Lastly, quantitative data are encrypted,  
21 uploaded and transferred nightly to the data analysis team where progress is reviewed in real time. On a  
22 nightly basis, qualitative data are removed from the recorders, saved on a password-protected  
23 computer, and tracked nightly.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 Data management

44  
45  
46 Survey data are captured on tablets and saved to the internal memory. During each round of  
47 data collection, each evening, a data team supervisor reviews the survey and encrypts it so survey data  
48 are no longer accessible on the tablet. The supervisor uploads encrypted data nightly during the  
49 collection period to a secure server administered by SurveyCTO (Version 2.212; Doherty, Inc.). The  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 evaluation team downloads the encrypted data using the SurveyCTO Client software (Version 2.212;  
4  
5 Dobility, Inc.), and decrypts the data using a decryption key generated by the research team.  
6

7  
8 The evaluation team oversees data entry, management, and storage for qualitative data. All IDIs  
9  
10 are translated into English and transcribed verbatim. Digital recorders and paper copies of written notes  
11  
12 are kept in a locked cabinet until transcriptions are checked for accuracy and completeness, at which  
13  
14 point audio files are deleted and notes are shredded. The electronic transcriptions do not contain  
15  
16 identifying information, only a study ID number linked to the quantitative survey. A separate linking file  
17  
18 for the quantitative and qualitative data is password protected and only accessible to the study team.  
19  
20  
21  
22

### 23 **Data analysis**

24  
25 The primary independent variable of interest is assignment to the intervention. For the analysis,  
26  
27 we will compare baseline characteristics between the intervention and control groups to assess balance.  
28  
29 We collect data on potential confounders to increase precision, analyze heterogeneity, and, if necessary,  
30  
31 control for any potential imbalance between the groups.  
32  
33

34 The primary dependent variable is the probability of facility delivery for most recent birth, based  
35  
36 on self-report by mothers. Secondary outcomes include:  
37

- 38 • Use of MWHs for antenatal care, delivery or postnatal services
- 39
- 40 • Delivery by cesaerean section
- 41
- 42 • Maternal death
- 43
- 44 • Neonatal death
- 45
- 46
- 47

48 We initially considered other secondary morbidity outcomes, but because the data were self-  
49  
50 reported and asked about experience up to 12 months before, there were limitations to what can  
51  
52 reasonably be asked without introducing major recall bias. The survey captures additional indicators of  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 complications including IV antibiotics, blood transfusions, and referral to CEmONC, but we have limited  
4  
5 secondary outcomes to those most likely to be clearly remembered.  
6

7  
8 All quantitative analyses will be conducted in SAS v9.4 (SAS, Cary, NC). Our quantitative analytic  
9  
10 plan is threefold, yielding descriptive, bivariate and multivariate statistics. First, we will describe the  
11  
12 study sample, stratifying by intervention and control group and testing for differences between the  
13  
14 groups. Second, we will estimate differences between the groups for primary and secondary outcomes,  
15  
16 controlling for a set of baseline demographics. . Categorical variables will be compared between the  
17  
18 groups using a chi-squared test when cell sizes are sufficient or Fisher's exact test when the cell sizes are  
19  
20 small; continuous variables will be compared using t-tests if normally distributed or non-parametric  
21  
22 Wilcoxon rank sum tests if the distribution is non-normal. Third, we will fit several regression models to  
23  
24 estimate the impact of the intervention on the primary and secondary outcomes, adjusting for baseline  
25  
26 values, assignment matching variables, and any imbalanced covariates. To control for the phased timing  
27  
28 of implementation, with MWHs opening at by including a variable in our main models that captures the  
29  
30 month the home opened.  
31  
32  
33

34  
35 All qualitative data will be analyzed in Nvivo 10 © software (QSR International Pty Ltd.). We will  
36  
37 conduct a content analysis of the IDI transcripts. Coding themes have been identified *a priori*. Additional  
38  
39 themes will be included as they emerge. We will triangulate findings with the quantitative data to  
40  
41 identify consistencies, inconsistencies or additional themes to be explored. We will use the themes  
42  
43 developed during the baseline analysis to analyze the endline data and identify any new themes as they  
44  
45 emerge.  
46  
47

48  
49 To systematically assess confounders and the risk of bias at the pre-intervention phase,  
50  
51 intervention phase, and post-intervention phase, we will use the ROBINS-I tool.[36] Guided by this tool,  
52  
53 we will transparently report threats to validity of this quasi-experimental study during analysis,  
54  
55  
56  
57  
58  
59

1  
2  
3 interpretation and dissemination. Results for the primary and each secondary evaluation question will  
4  
5 be presented.  
6

## 7 **ETHICS**

### 8 **Ethics approval and consent to participate**

#### 9 10 11 12 Ethical review boards

13  
14  
15 Prior to participant enrollment, ethical approvals were obtained from the Boston University Institutional  
16  
17 Review Board (IRB), University of Michigan IRB (for a de-identified dataset only), and the ERES Converge  
18  
19 Research IRB, a private local ethics board in Zambia. We also obtained official approval to proceed with  
20  
21 the study from the Zambia National Health Research Authority, which is responsible for oversight of all  
22  
23 research conducted in the country. Adverse events, unanticipated problems and any protocol changes  
24  
25 will be reported to the IRBs and the Zambia National Health Research Authority per their guidelines, and  
26  
27 all investigators will be informed.  
28  
29

#### 30 31 32 Potential risks and protections

33  
34 This study poses minimal risk to study participants and several steps were taken to minimize risk and  
35  
36 burden. To reduce the risk of disclosure of personal or sensitive information enumerators are trained to  
37  
38 stop participants from disclosing information that is too sensitive. Participation may cause some  
39  
40 discomfort from answering certain questions, particularly if the maternal or neonatal health outcomes  
41  
42 were adverse. Enumerators are trained to minimize any potential discomfort or harm to all participants  
43  
44 during all study activities to the greatest extent possible. We minimize any waiting by participants by  
45  
46 scheduling meetings during times convenient to participants and interviews are kept to as short of time  
47  
48 as possible taking breaks if necessary.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Potential benefits

There are no direct individual benefits to participating in the study. The evaluation results will generate evidence on the impact of MWHs on facility delivery for those who live farthest away. Findings will provide insight for policy makers into how, if found to be effective, MWHs can be part of a broader strategy to improve maternal and neonatal health outcomes.

## Participant confidentiality

Throughout the study, we take care to ensure the confidentiality of data obtained from study participants. The HHSs and IDIs are carried out in participants' private homes or somewhere the participant feels comfortable. We do not proceed with data collection until we can confirm that the location is acceptable and participants agree that they feel comfortable discussing study topics.

The linking file with identifiable data and basic demographics is stored in a separate file within the tablet system. Upon completion of data collection, all files are stored on a secure server during data analysis and report writing. Only BU/RTC investigators have access to identifiable data. All analyses by study partners are conducted on de-identified datasets per IRB approvals. Analyses are presented in aggregate format in technical reports to stakeholders and in manuscripts submitted for publication in scientific journals. Under no circumstances do organizations or individuals have access to the participant's individual demographic information and potential identifying information (job title, age range, sex, and village). As explained above, the qualitative data are de-identified, with basic demographics only.

## Informed consent

Prior to any data collection, we discuss the purpose of the study with local leaders so that the study activities are clearly understood. If a household is eligible, the study team proceeds with the informed voluntary consent process from the household head or the most senior woman in the

1  
2  
3 household, introducing themselves, the purpose of the study, and explaining what we are asking of  
4 them in terms of participation, the risks and benefits, the right to withdraw without penalty at any time,  
5 that their information will be kept in a safe location, and that their answers will not be linked to their  
6 names. Participants are informed that the alternative is to not participate in the study. The study team  
7 slowly and clearly asks for consent to participate. If a selected household participant declines  
8 participation, the next household on the randomly ordered list of eligible households is contacted. If a  
9 household head or senior woman consents to participating, the study team documents written  
10 informed consent and proceeds with the interview. In addition to the household head or a senior  
11 woman, using the same process we also consent the woman selected from within the household to  
12 respond to the survey; in some cases, this may be the same person. A maximum of two individuals are  
13 consented per household.

14  
15  
16 We anticipate about 15% of the sample in each round to be between 15-17 years of age. In  
17 Zambia, 'emancipated minors' can enroll if they provide assent and their guardian or husband also  
18 provides consent. If a woman's husband is 18 or older, then he can provide informed consent on behalf  
19 of his wife; however, if he is also under 18 years old, then her legal guardian must provide consent. If  
20 under 18, the research team will allow the woman to first determine if she wishes to join the study  
21 (assent is provided) and then obtain consent by the guardian or husband. Thus, the individual's wishes  
22 are protected and she can determine if she wishes to be part of the study.

23  
24  
25 All informed consent or assent/consent is documented with a signature; in the event a  
26 participant cannot write, a witness signs the informed consent. A participant retains a copy of the  
27 informed consent form. The informed consent and assent processes are always conducted in the  
28 language most preferred by the participant.

## Costs and payments

For all activities, the participants volunteer only the time taken to complete this survey. There is no cash payment provided to participants for any portion of the study. Participants receive pieces of fabric as small tokens of appreciation in recognition of their time and opportunity costs, in line with local IRB procedures.

## Limitations

This study has several limitations. First, half of study clusters could not be randomly assigned to either the intervention or control group due to political constraints and concern by the government about community fatigue. The selection bias resulting from the different assignment strategies is partially mitigated by ensuring comparison sites are matched on the same criteria as the other sites. Additionally, because one partner's comparison sites include existing MWHs as part of standard of care, and the other partner excluded sites with existing MWHs in , we will analyze the full sample as a quasi-experimental CBA study and we will estimate the impact in both the non-randomized and randomized subsamples to assess potential bias introduced by non-random assignment and the differences in comparison site selection. Second, we limited household eligibility to those living at least 10 km from the health facilities and will not be able to assess impact on women living nearer to facilities. However, remote women are the primary target of the MWH model and stand to benefit the most from the intervention. To manage this limitation, in separate process evaluation protocols, each partner is collecting facility-based data to understand any changes in demographics among those utilizing facilities for delivery using agreed upon indicators and data sources. Lastly, because there are two implementing partners, there is a risk that the MWH model will be implemented differently across the sites. To mitigate this risk, we have developed and agreed upon the precise elements of the MWH model based

on both partners' formative research [24–26] and will be assessing implementation fidelity using harmonized tools in the companion process evaluation protocols.

## REFERENCES

- 1 The United Nations. Goal 3 .. Sustainable Development Knowledge Platform. <https://sustainabledevelopment.un.org/sdg3> (accessed 2 Feb 2018).
- 2 Central Statistical Office (CSO) Zambia, [Ministry of Health (MOH) [Zambia], ICF International. Zambia Demographic and Health Survey 2013-14. Rockville, Maryland, USA: 2014.
- 3 UN General Assembly. Resolution adopted by the General Assembly on 25 September 2015 70/1. Transforming our world: the 2030 Agenda for Sustainable Development. 2030. [http://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A\\_RES\\_70\\_1\\_E.pdf](http://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A_RES_70_1_E.pdf) (accessed 17 Jan 2018).
- 4 Republic of Zambia Ministry of Health. National Health Strategic Plan 2011 - 2015. 2011;:119.
- 5 Republic of Zambia Ministry of Health. Roadmap for Accelerating Reduction of Maternal , Newborn and Child Mortality , 2013-2016. 2016;:2013–6.
- 6 Gabrysch S, Cousens S, Cox J, *et al*. The influence of distance and level of care on delivery place in rural Zambia: a study of linked national data in a geographic information system. *PLoS Med* 2011;**8**. doi:10.1371/journal.pmed.1000394
- 7 Gabrysch S, Campbell OM, Lawn J, *et al*. Still too far to walk: Literature review of the determinants of delivery service use. *BMC Pregnancy Childbirth* 2009;**9**:34. doi:10.1186/1471-2393-9-34
- 8 Lohela TJ, Campbell OMR, Gabrysch S, *et al*. Distance to Care, Facility Delivery and Early Neonatal Mortality in Malawi and Zambia. *PLoS One* 2012;**7**:e52110. doi:10.1371/journal.pone.0052110
- 9 Sialubanje C, Massar K, Hamer DH, *et al*. Understanding the psychosocial and environmental factors and barriers affecting utilization of maternal healthcare services in Kalomo, Zambia: A qualitative study. *Health Educ Res* 2014;**29**:521–32. doi:10.1093/her/cyu011
- 10 Stekelenburg J, Van Lonkhuijzen L, Spaans W, *et al*. Maternity waiting homes in rural districts in Africa: A cornerstone of safe motherhood? *Curr Womens Health Rev* 2006;**2**:235–8. doi:10.2174/157340406778699914
- 11 Lori JR, Wadsworth AC, Munro ML, *et al*. Promoting access: The use of maternity waiting homes to achieve safe motherhood. *Midwifery* 2013;**29**:1095–102. doi:10.1016/j.midw.2013.07.020
- 12 Kelly J, Kohls E, Poovan P, *et al*. The role of a maternity waiting area (MWA) in reducing maternal mortality and stillbirths in high-risk women in rural Ethiopia. *BJOG* 2010;**117**:1377–83. doi:10.1111/j.1471-0528.2010.02669.x
- 13 Henry EG, Semrau K, Hamer DH, *et al*. The influence of quality maternity waiting homes on utilization of facilities for delivery in rural Zambia. *Reprod Health* 2017;**14**:68.

- 1  
2  
3 doi:10.1186/s12978-017-0328-z
- 4 14 Fogliati P, Straneo M, Mangi S, *et al.* A new use for an old tool: maternity waiting homes  
5 to improve equity in rural childbirth care. Results from a cross-sectional hospital and  
6 community survey in Tanzania. *Health Policy Plan* 2017;**32**:1354–60.  
7 doi:10.1093/heapol/czx100
- 8  
9 15 García Prado A, Cortez R. Maternity waiting homes and institutional birth in Nicaragua:  
10 policy options and strategic implications. *Int J Health Plann Manage* 2012;**27**:150–66.  
11 doi:10.1002/hpm.1107
- 12  
13 16 Chandramohan D, Cutts F, Millard P. The effect of stay in a maternity waiting home on  
14 perinatal mortality in rural Zimbabwe. *J Trop Med Hyg* 1995;**98**:261–  
15 7.<http://www.ncbi.nlm.nih.gov/pubmed/7636923> (accessed 12 Dec 2016).
- 16  
17 17 Chandramohan D, Cutts F, Chandra R. Effects of a maternity waiting home on adverse  
18 maternal outcomes and the validity of antenatal risk screening. *Int J Gynecol Obstet*  
19 1994;**46**:279–84. doi:10.1016/0020-7292(94)90406-5
- 20  
21 18 Gaym A, Pearson L, Soe KWW. Maternity waiting homes in Ethiopia--three decades  
22 experience. *Ethiop Med J* 2012;**50**:209–19.
- 23  
24 19 Van Lonkhuijzen L, Stegeman M, Nyirongo R, *et al.* Use of Maternity Waiting Home in  
25 Rural Zambia. *Afr J Reprod Health* 2003;**7**:32–6. doi:10.1108/10650750910961929
- 26  
27 20 Andemichael G, Haile B, Kosia A, *et al.* Maternity waiting homes: A panacea for  
28 maternal/neonatal conundrums in Eritrea. *J Eritrean Med Assoc* 2009;**4**:18–21.  
29 doi:10.4314/jema.v4i1.52112
- 30  
31 21 van Lonkhuijzen L, Stekelenburg J, van Roosmalen J. Maternity waiting facilities for  
32 improving maternal and neonatal outcome in low-resource countries. *Cochrane database*  
33 *Syst Rev* 2012;**10**:CD006759. doi:10.1002/14651858.CD006759.pub3
- 34  
35 22 Wild K, Barclay L, Kelly P, *et al.* The tyranny of distance: maternity waiting homes and  
36 access to birthing facilities in rural Timor-Leste. *Bull World Health Organ* 2012;**90**:97–  
37 103. doi:10.2471/BLT.11.088955
- 38  
39 23 Ministry of Health (MOH) [Zambia]. Zambia National Health Strategic Plan 2017-2021.  
40 2017.
- 41  
42 24 Chibuye PS, Bazant ES, Wallon M, *et al.* Experiences with and expectations of maternity  
43 waiting homes in Luapula Province, Zambia: a mixed-methods, cross-sectional study with  
44 women, community groups and stakeholders. *BMC Pregnancy Childbirth* 2018;**18**:42.  
45 doi:10.1186/s12884-017-1649-1
- 46  
47 25 Lori JR, Munro-Kramer ML, Mdluli EA, *et al.* Developing a community driven sustainable  
48 model of maternity waiting homes for rural Zambia. *Midwifery* 2016;**41**:89–95.  
49 doi:10.1016/j.midw.2016.08.005
- 50  
51 26 Scott NA, Vian T, Kaiser JL, *et al.* Listening to the community: Using formative research to  
52 strengthen maternity waiting homes in Zambia. *PLoS One* 2018;**13**. doi:<https://doi.org/10.1371/journal.pone.0194535>
- 53  
54 27 Central Statistical Office (CSO) Zambia. 2010 Census of Population and Housing -  
55 Southern Province Analytical Report. Lusaka: 2014.  
56 <http://web0.psa.gov.ph/statistics/census/population-and-housing>
- 57  
58 28 Central Statistical Office (CSO) Zambia. 2010 Census of Population and Housing - Eastern  
59 Province Analytical Report. Lusaka: 2014.  
60

- 1  
2  
3  
4 [https://www.zamstats.gov.zm/phocadownload/2010\\_Census/2010\\_Census\\_Analytical\\_Reports/Eastern Province Analytical Report - 2010 Census.pdf](https://www.zamstats.gov.zm/phocadownload/2010_Census/2010_Census_Analytical_Reports/Eastern_Province_Analytical_Report_-_2010_Census.pdf) (accessed 19 Jan 2018).
- 5  
6 29 Central Statistical Office (CSO) Zambia. Zambia 2010 Census of Population and Housing  
7 Population Summary Report. Lusaka: 2012. [http://www.mcaz.gov.zm/wp-](http://www.mcaz.gov.zm/wp-content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf)  
8 [content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf](http://www.mcaz.gov.zm/wp-content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf) (accessed 19  
9 Jan 2018).
- 10  
11 30 Zambian Ministry of Health. The 2012 List of Health Facilities in Zambia: Preliminary  
12 Report, v15. 2013;:252.
- 13  
14 31 SMGL. Saving Mothers Giving Life - Home.  
15 2016.<https://www.savingmothersgivinglife.org/> (accessed 16 Nov 2016).
- 16  
17 32 Bernard HR. *Social Research Methods Qualitative and Quantitative Approaches*. 2nd ed.  
18 USA: : SAGE Publications, Inc 2013.
- 19  
20 33 Hamer DH, Herlihy JM, Musokotwane K, *et al*. Engagement of the Community,  
21 Traditional Leaders, and Public Health System in the Design and Implementation of a  
22 Large Community-Based, Cluster-Randomized Trial of Umbilical Cord Care in Zambia. *Am J Trop Med Hyg* 2015;**92**:666–72. doi:10.4269/ajtmh.14-0218
- 23  
24 34 Semrau KEA, Herlihy J, Grogan C, *et al*. Effectiveness of 4% chlorhexidine umbilical cord  
25 care on neonatal mortality in Southern Province, Zambia (ZamCAT): a cluster-randomised  
26 controlled trial. *Lancet Glob Heal* 2016;**4**:e827–36. doi:10.1016/S2214-109X(16)30215-7
- 27  
28 35 Pagel C, Prost A, Lewycka S, *et al*. Intracluster correlation coefficients and coefficients of  
29 variation for perinatal outcomes from five cluster-randomised controlled trials in low and  
30 middle-income countries: results and methodological implications. *Trials* 2011;**12**:151.  
31 doi:10.1186/1745-6215-12-151
- 32  
33 36 Sterne JA, Hernán MA, Reeves BC, *et al*. ROBINS-I: a tool for assessing risk of bias in non-  
34 randomised studies of interventions. *BMJ* 2016;**355**:i4919. doi:10.1136/BMJ.i4919

## 35 36 **AUTHORS STATEMENT**

37  
38  
39 NS led the scientific design, implementation, and was primarily responsible for drafting this manuscript.  
40  
41 JK contributed to the development of the protocol, led the development of the study sample,  
42  
43 coordinated data collection, and contributed to revisions of the manuscript. TV and RB contributed to  
44  
45 the revisions and science of the protocol and data collection instruments. RF contributed to the  
46  
47 development of the protocol, implemented the electronic data capture system, and contributed to the  
48  
49 revisions of this manuscript. TN, GB, CB, and JL provided feedback on the protocol and reviewed and  
50  
51 edited the final manuscript. DH provided scientific support, technical input into the survey design and  
52  
53 critically reviewed and edited the final manuscript. PR helped conceptualize the scientific design of the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 study, provided technical input into the survey design, sampling approach, and critically reviewed and  
4  
5 edited the final manuscript. All authors read and approved the final version of the manuscript.  
6

## 7 8 **FUNDING**

9  
10 This program was developed and is being implemented in collaboration with *MSD for Mothers*, MSD's  
11  
12 10-year, \$500 million initiative to help create a world where no woman dies giving life. *MSD for*  
13  
14 *Mothers* is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A. (MRK 1846-06500.COL). The  
15  
16 development of this article was additionally supported in part by the Bill & Melinda Gates Foundation  
17  
18 (OPP1130329) [https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-](https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/07/OPP1130329)  
19  
20 [Database/Grants/2015/07/OPP1130329](https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/07/OPP1130329) and The ELMA Foundation (ELMA-15-F0017)  
21  
22 <http://www.elmaphilanthropies.org/the-elma-foundation/>. The funders had no role in study design,  
23  
24 data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely  
25  
26 the responsibility of the authors and does not reflect positions or policies of MSD, the Bill & Melinda  
27  
28 Gates Foundation or The ELMA Foundation.  
29  
30  
31  
32  
33

## 34 35 **CONFLICTS OF INTEREST STATEMENT**

36  
37 The authors declare that they have no competing interests.  
38  
39  
40  
41

## 42 43 **FIGURE LEGEND**

44 **Figure 1. Minimum Maternity Waiting Home Model in the Maternity Home Alliance for Intervention**  
45  
46 **Sites (n=20).**

47  
48  
49 **Figure 2. Map of the Maternity Home Alliance Intervention and Control Study Sites by Partner**

50  
51 **Figure 3. Multi-stage Random Sampling Strategy for Baseline and Endline**  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Minimum Maternity Waiting Home Model in the Maternity Home Alliance for Intervention Sites (n=20).

101x66mm (300 x 300 DPI)






Figure 2. Map of the Maternity Home Alliance Intervention and Control Study Sites by Partner

173x144mm (300 x 300 DPI)

only




Figure 3. Multi-stage Random Sampling Strategy for Baseline and Endline

97x54mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___1___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___3,clinicaltrials.gov
	2b	All items from the World Health Organization Trial Registration Data Set	1-23 and on clinicaltrials.gov
Protocol version	3	Date and version identifier	___na___
Funding	4	Sources and types of financial, material, and other support	___23___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___1___
	5b	Name and contact information for the trial sponsor	___23___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___23___

1			
2			
3		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
4			_____na_____
5			
6			
7			
8			
9			
10			
11	<b>Introduction</b>		
12			
13	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
14			_____5,6_____
15		6b	Explanation for choice of comparators
16			_____8_____
17	Objectives	7	Specific objectives or hypotheses
18			_____5,6_____
19			
20	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
21			_____8_____
22			
23			
24	<b>Methods: Participants, interventions, and outcomes</b>		
25	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
26			_____7_____
27			
28	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
29			_____8,9,12_____
30			
31	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
32			_____6_____
33		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
34			_____na_____
35		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
36			_____na_____
37		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
38			_____na_____
39			
40			
41			
42			
43			
44			
45			
46			
47			

1				
2				
3	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	____ 6,7,16 ____
4				
5				
6				
7				
8	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	____ 11 ____
9				
10				
11	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	____ 11 ____
12				
13				
14	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	____ 13 ____
15				

### 16 **Methods: Assignment of interventions (for controlled trials)**

#### 17 Allocation:

18				
19				
20	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	____ 9, 12, 13, ____
21				
22				
23				
24				
25	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	____ na ____
26				
27				
28				
29	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	____ na ____
30				
31				
32				
33	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	____ na ____
34				
35				
36		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	____ na ____
37				
38				

### 39 **Methods: Data collection, management, and analysis**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____6-14_____
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____na_____
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____14, 15_____
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____15, 16_____
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____16_____
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____na_____
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____na_____
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____na_____
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____16, 17_____
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____na_____

**Ethics and dissemination**

1				
2				
3	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____16_____
4				
5				
6	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____16, 17_____
7				
8				
9				
10	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____18, 19_____
11				
12				
13		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____na_____
14				
15				
16	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____17, 18_____
17				
18				
19	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____23_____
20				
21				
22	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____18_____
23				
24				
25	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____na_____
26				
27				
28	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____19_____
29				
30				
31				
32		31b	Authorship eligibility guidelines and any intended use of professional writers	_____22, 23_____
33				
34		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____na_____
35				
36	<b>Appendices</b>			
37				
38	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__Can be provided upon request__
39				
40				
41				
42				
43				
44				
45				
46				
47				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____na_____
----------------------	----	--	--------------

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only



# BMJ Open

## Impact of maternity waiting homes on facility delivery among remote households in Zambia: protocol for a quasi-experimental, mixed-methods study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022224.R2
Article Type:	Protocol
Date Submitted by the Author:	12-Jul-2018
Complete List of Authors:	Scott, Nancy; Boston University School of Public Health, Global Health Kaiser, Jeanette; Boston University School of Public Health, Global Health Vian, Taryn; Boston University School of Public Health, Global Health Bonawitz, Rachael; Boston University School of Public Health, Global Health; Boston University School of Medicine, Pediatrics Fong, Rachel; Boston University School of Public Health, Global Health Ngoma, Thandiwe; Right to Care Zambia Biemba, Godfrey; National Health Research Authority, Pediatric Centre of Excellence Boyd, Carol; University of Michigan School of Nursing, Health Behavior & Biological Sciences Lori, Jody; University of Michigan School of Nursing, Center for Global Affairs & PAHO/WHO Collaborating Center Hamer, D.; Boston University, Rockers, Peter; Boston University, Department of Global Health
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Research methods, Global health, Qualitative research
Keywords:	maternity waiting home, maternal health, skilled birth attendance, mixed methods, impact evaluation, Zambia

SCHOLARONE™  
Manuscripts

**Title:** *Impact of maternity waiting homes on facility delivery among remote households in Zambia: protocol for a quasi-experimental, mixed-methods study*

**Authors:**

Name	Institutional Address	Email Address
Nancy Scott	Department of Global Health, Boston University School of Public Health, Boston, USA 801 Massachusetts Ave, Boston, MA 02118	<a href="mailto:nscott@bu.edu">nscott@bu.edu</a> (corresponding) Tel: +1-617-414-1278
Jeanette Kaiser	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:jkaiser@bu.edu">jkaiser@bu.edu</a>
Taryn Vian	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:tvian@bu.edu">tvian@bu.edu</a>
Rachael Bonawitz	Department of Global Health, Boston University School of Public Health Boston, MA USA Department of Pediatrics, Boston University School of Medicine Boston, MA USA	<a href="mailto:rebonawi@bu.edu">rebonawi@bu.edu</a>
Rachel Fong	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:rmfong@bu.edu">rmfong@bu.edu</a>
Thandiwe Ngoma	Right to Care-Zambia Lusaka, Zambia	<a href="mailto:ngoma.thandiwe@gmail.com">ngoma.thandiwe@gmail.com</a>
Godfrey Biemba	National Health Research Authority, Pediatric Centre of Excellence Lusaka, Zambia	<a href="mailto:gbiemba@gmail.com">gbiemba@gmail.com</a>
Carol J. Boyd	Department of Health Behavior & Biological Sciences School of Nursing, University of Michigan Ann Arbor, MI USA	<a href="mailto:caro Boyd@med.umich.edu">caro Boyd@med.umich.edu</a>
Jody R. Lori	Center for Global Affairs & PAHO/WHO Collaborating Center School of Nursing, University of Michigan Ann Arbor, MI USA	<a href="mailto:jrlori@umich.edu">jrlori@umich.edu</a>
Davidson H. Hamer	Department of Global Health, Boston University School of Public Health Boston, MA USA  Section of Infectious Diseases, Department of Medicine, Boston Medical Center Boston, MA USA	<a href="mailto:dhamer@bu.edu">dhamer@bu.edu</a>
Peter C. Rockers	Department of Global Health, Boston University School of Public Health Boston, MA USA	<a href="mailto:prockers@bu.edu">prockers@bu.edu</a>

**Word count:** 4,200 (excluding title page, abstract, references, figures and tables)

## List of Acronyms

Africare/UM	Africare/University of Michigan
ANC	Antenatal care
BEmONC	Basic emergency obstetric and newborn care
BU/RTC	Boston University/Right to Care Zambia
CBA	Controlled before-and-after
CEmONC	Comprehensive emergency obstetric and newborn care
GRZ	Government of the Republic of Zambia
HHS	Household survey
IDI	In-depth interview
IRB	Institutional review board
MHA	Maternity Homes Alliance
MMR	Maternal mortality ratio
MSD	Merck Sharp & Dohme
MWH	Maternity Waiting Home
PNC	Postnatal care
SDG	Sustainable Development Goals

## ABSTRACT

**Introduction:** Maternity waiting homes (MWHs) aim to improve access to facility delivery in rural areas. However, there is limited rigorous evidence of their effectiveness. Using formative research, we developed a MWH intervention model with three components: infrastructure, management, and linkage to services. This protocol describes a study to measure the impact of the MWH model on facility delivery among women living farthest ( $\geq 10$ km) from their designated health facility in rural Zambia. This study will generate key new evidence to inform decision making for MWH policy in Zambia and globally.

**Methods and analysis:** We are conducting a mixed-methods quasi-experimental impact evaluation of the MWH model using a controlled before-and-after design in 40 health facility clusters. Clusters were assigned to the intervention or control group using two methods: 20 clusters were randomly assigned using a matched-pair design; the other 20 were assigned without randomization due to local political constraints. Overall, 20 study clusters receive the MWH model intervention while 20 control clusters continue to implement the 'standard of care' for waiting mothers. We recruit a repeated cross-section of 2,400 randomly sampled recently-delivered women at baseline (2016) and endline (2018); all participants are administered a household survey and a 10% subsample also participates in an in-depth interview. We will calculate descriptive statistics and adjusted odds ratios; qualitative data will be analyzed using content analysis. The primary outcome is the probability of delivery at a health facility; secondary outcomes include utilization of MWHs and maternal and neonatal health outcomes.

**Ethics and dissemination:** Ethical approvals were obtained from the Boston University Institutional Review Board (IRB), University of Michigan IRB (de-identified data only), and the ERES Converge IRB in Zambia. Written informed consent is obtained prior to data collection. Results will be disseminated to key stakeholders in Zambia, then through open-access journals, websites, and international conferences.

**Trial Registration:** ClinicalTrials.gov Identifier: NCT02620436

**Keywords:** maternity waiting home, maternal health, facility delivery, mixed methods, impact evaluation, Zambia

## ARTICLE SUMMARY

### Strengths and limitations of this study

This study has several strengths and limitations, including:

- To the best of our knowledge, this is the first large-scale impact evaluation of MWHs, employing a rigorous controlled before-and-after, quasi-experimental design and using mixed-methods.
- For generalizability, a representative sample of recently-delivered women living most remotely is selected using a multi-stage, random sampling strategy for both the quantitative household surveys and the qualitative in-depth interviews.
- Half of study clusters could not be randomly assigned to either the intervention or control group due to political constraints, resulting in quasi-experimental study design.
- Because remote women stand to benefit the most from the MWH model, eligibility is limited to those living at least 10km from the health facilities; findings will therefore not be able to assess impact of the intervention on women living nearer to facilities.
- In companion protocols, implementation fidelity of the core elements of the MWH model is assessed by each partner using harmonized tools.

## INTRODUCTION

The Sustainable Development Goals (SDGs) include a target of reducing the global maternal mortality ratio (MMR) to less than 70 deaths per 100,000 live births by 2030.[1] Zambia's MMR is currently 398 deaths per 100,000 live births, well above the SDG target.[2,3] Skilled care at every birth, one of the two SDG indicators for MMR, is recommended. What remains unanswered is how to best facilitate access to intrapartum and postpartum care, particularly in rural and remote areas where distance and poor transportation severely restrict access to care. The Government of the Republic of Zambia (GRZ) is committed to improving maternal health and encourages facility-based delivery for all women,[4,5] though accessing facilities for birth is challenging for women living in remote areas.[6–9]

Maternity waiting homes (MWHs) are lodgings located near health facilities where mothers who are close to term can await delivery. These homes are meant to provide pregnant women with the option of planning ahead and traveling to health facilities well before labor begins. MWHs may be a promising strategy to improve access to facilities for delivery, the evidence is mixed. While some evidence suggests they are associated with higher rates of facility delivery and improved maternal health outcomes,[10–20] a Cochrane review found that there are no randomized or quasi-randomized trials assessing the effectiveness of MWHs in low-resource settings.[21] Additionally, it is unclear if MWHs can increase access to facility delivery among women living most remotely.[19,22] Rigorous evidence on the impact of MWHs on facility deliveries is needed.

This protocol describes a study being conducted by the Maternity Homes Alliance (MHA), a partnership between the GRZ, Boston University and Right to Care Zambia, formerly the Zambian Center for Applied Health Research and Development (BU/RTC), Africare and the University of Michigan (Africare/UM), and funded by Merck Sharp and Dohme (MSD) for Mothers, the Bill & Melinda Gates Foundation, and The ELMA Foundation. The MHA hypothesizes that MWHs can remove the distance

1  
2  
3 barrier and increase access to facility-based delivery. In this study, we test the impact of MWHs on  
4 facility delivery among women living at least 10km from health facilities in rural Zambia.  
5  
6

7  
8 MWHs have the potential to improve access to facility delivery, particularly for women in rural  
9 areas living far from health facilities. Despite their widespread use in developing countries, there is  
10 currently little evidence of MWH effectiveness. Using community input, we developed a MWH model  
11 and are evaluating it for impact. To the best of our knowledge, this is the first large-scale impact  
12 evaluation of MWHs. Findings will generate evidence surrounding the effectiveness of MWHs on  
13 improving facility deliveries for remote populations in Zambia and other countries with similar rural and  
14 highly dispersed populations.  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **Intervention**

25  
26  
27 While the government of Zambia supports the use of MWHs as a strategic method to increase  
28 access to skilled birth attendance [5,23] and MWHs have existed in Zambia for decades, there is no  
29 specific policy or plan for the scale-up of MWHs and their general quality remains low.[13,24–26] MWHs  
30 have been largely constructed through community initiatives or international donors, with limited  
31 support for their long-term maintenance.[24–26] Formative evaluations conducted previously by  
32 members of the study team in the current study setting showed that MWHs could be an acceptable and  
33 feasible option to improve access to facilities for delivery.[24–26] Informed by these findings, the core  
34 MWH model was designed to be responsive to community expectations, community-defined standards  
35 of acceptability and their perceptions of quality including safety, comfort, management and services  
36 offered (Figure 1). In direct response to the formative data, the model includes the following:  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

- 50 • **Infrastructure, Supplies and Equipment:** The core MWH model has concrete walls and floors,  
51 roofs that do not leak, latrines, a private bathing space, water within a reasonable distance, a  
52 covered cooking space, and storage space. For safety, the core MWH model has lockable doors,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 windows, cupboards, and lighting. Amenities include beds, mattresses, bedding, mosquito nets,  
4  
5 and cooking utensils.  
6  
7

- 8 • **Policies, Management and Finances:** The core MWH model is community-owned and operated,  
9  
10 as requested by the Ministry of Health. The policies, management, and financial structures are  
11  
12 adaptable to site-specific needs and preferences, though all have a formalized governance and  
13  
14 management structure with community, government and health facility representation. Each  
15  
16 also has a management unit responsible for daily operations including registering and orienting  
17  
18 women, record keeping and maintenance.  
19  
20
- 21 • **Linkages & Services:** Each core MWH model is situated close to the health facility to ensure  
22  
23 timely access to clinical care when a woman's labor begins. A health facility staff provides daily  
24  
25 check-ins with waiting women, though clinical care visits continue to be conducted at the health  
26  
27 facility, not in the MWH. Women staying at the MWH have the opportunity to participate in  
28  
29 maternal and child education courses offered by the health facility staff or community health  
30  
31 workers.  
32  
33  
34  
35  
36  
37  
38

39 **INSERT FIGURE 1**  
40  
41  
42  
43

44 The core MWH model is promoted in the community through several mechanisms. First, health  
45  
46 facility staff promote the MWH at all ANC visits. Over 95% of women attend at least the first ANC visit ,  
47  
48 so most women are exposed at the health facility.[2] Second, Safe Motherhood Action Group members  
49  
50 promote the use of MWHs during their routine outreach activities. Lastly, the traditional leadership  
51  
52 (chiefs and headmen) actively promotes the use of MWHs at their community meetings. The MWH  
53  
54 model targets all pregnant women within 1-2 weeks of their estimated delivery date resident within the  
55  
56  
57  
58  
59



1  
2  
3 catchment area, prioritizing those women living farthest away (i.e. > 10 km from the health facility). The  
4  
5 20 MWHs opened in phases between mid-2016 and mid-2017.  
6  
7

## 8 **METHODS**

9

### 10 **Evaluation questions**

11  
12  
13 The primary research question is:

- 14 1. What is the impact of the MWH model on the probability of facility delivery among mothers  
15  
16 living more than 10 km from the health facility?  
17  
18

19  
20  
21 Secondary questions include:

- 22 1. Do awareness and perceptions of health facility-associated safe delivery and health facility  
23  
24 delivery intention among pregnant women living in communities located more than 10 km from  
25  
26 the health facility change over time in MWH model sites?  
27  
28
- 29 2. How do awareness and perceptions of MWHs by communities located more than 10 km from  
30  
31 the health facility change over the period of this study?  
32  
33
- 34 3. What financial impact does the use of the MWH model have on the families of women who  
35  
36 utilize it?  
37  
38
- 39 4. How does the perception of quality and acceptability differ between MWH model sites and  
40  
41 comparison sites?  
42  
43
- 44 5. What is the impact of the MWH model on maternal and neonatal health outcomes among those  
45  
46 living more than 10 km from the facility?  
47  
48

### 49 **Study setting**

50  
51 This study began in March 2016 and will be completed in December 2018. The intervention and  
52  
53 comparison sites are located in the primarily rural Zambian districts of Choma, Kalomo and Pemba  
54  
55  
56  
57  
58  
59

1  
2  
3 Districts of Southern Province; Nyimba and Lundazi Districts of Eastern Province; and Mansa and  
4  
5 Chembe Districts of Luapula Province (Figure 2).  
6

## 7 8 **INSERT FIGURE 2** 9

10  
11 Choma district has a population of 247,860 and a population density of 34/km<sup>2</sup>, with 68.7% of its  
12  
13 population being rural. Kalomo district has a population of 258,570 and a population density of  
14  
15 17.2/km<sup>2</sup>, with 91.8 percent of its population being rural.[27] Nyimba district has a population of 85,025  
16  
17 and a population density of 8.1/km<sup>2</sup>, with 91 percent of its population being rural. Lundazi district has a  
18  
19 population of 323,870 and a population density of 23/km<sup>2</sup>, with 95.1 percent of its population being  
20  
21 rural.[28] Mansa district has a population of 228,392 and a population density of 23.1/km<sup>2</sup>, with 61.9  
22  
23 percent of its population being rural.[29]  
24  
25  
26  
27  
28  
29

## 30 31 **Study design** 32

33 This study employs a quasi-experimental controlled before-and-after (CBA) design with a total of  
34  
35 40 study clusters, 20 intervention and 20 control clusters. Clusters consist of health facilities and their  
36  
37 catchment households. Intervention clusters are receiving the MWH model, inclusive of newly  
38  
39 constructed homes with the elements from the three domains: (1) infrastructure, equipment and  
40  
41 supplies; 2) policies, management and finances; and 3) linkages and services detailed in the intervention  
42  
43 section of the protocol. Control clusters are implementing the 'standard of care' for waiting mothers in  
44  
45 Zambia. Because no national policy exists, the standard of care is facility-driven and varies widely. Some  
46  
47 standard-of-care facilities have no designated space for a mother to wait; others have no MWH but  
48  
49 provide a designated space for waiting mothers within the clinic; and a small number have an existing  
50  
51 MWH-like structure but with highly variable quality.[13]  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Eligibility criteria of study clusters

Because the intervention aims to generate demand for health facility delivery, it is critical that facilities are capable of managing basic emergency obstetric and neonatal complications (BEmONC). Because of inconsistencies in available secondary data sources across the different districts, we established supplemental criteria that could be drawn from the available sources.[30,31] Clusters were eligible for inclusion in the study if the health facility was located  $\leq 2$  hours driving time to a comprehensive emergency obstetric and neonatal care (CEmONC) capable referral facility, performed a minimum of 150 deliveries per year AND met at least one of two sets of conditions below:

### Eligibility condition set 1:

- i. Facility is able to provide at least 5 of 7 BEmONC signal functions based on 2015 data;

### Eligibility condition set 2:

- i. Facility has at least one skilled birth attendant on staff;
- ii. Facility routinely provide active management of third stage of labor;
- iii. Facility has had no stock outs of oxytocin in the last 12 months;
- iv. Facility has had no stock outs of magnesium sulfate in the last 12 months;

## Selection and assignment of study clusters to study arm

There is a total of 40 clusters (20 intervention, 20 comparison) in this study (Table 1). Each implementing partner used different methods to select and assign clusters to study arms. One partner had a total of 36 eligible health facilities that were located  $\leq 2$  hours driving time to a referral facility and performed a minimum of 150 deliveries. Of those, 22 (61%) met one of the two eligibility conditions. This partner selected the 20 farthest away from referral, created 10 pairs matched on annual delivery volume and distance, then randomized matched pairs to intervention or control, using the RAND

function in Microsoft Excel®. Sites in each arm were included, regardless if it had an existing infrastructure or space that functioned as a MWH, and considered standard of care. Those with existing infrastructure were not structurally sound.

**Table 1:** Quasi-experimental study design to evaluate the impact of MWHs

Randomized subsample (n=20 clusters)	Non-randomized subsample (n=20 clusters)	Non-randomized full sample (n=40 clusters)
R O1 X O2	NR O1 X O2	NR O1 X O2
R O1 _ O2	NR O1 _ O2	NR O1 _ O2

*X = Minimum Core Maternity Home (see above)*

*O = Observations at baseline (O1, in 2016) and endline (O2, in 2018) at intervention (X) and comparison ( \_ ) sites.*

*R = cluster randomized; NR = not randomized*

The other partner had a total of 29 eligible health facilities that were located  $\leq 2$  hours driving time to a referral facility and performed a minimum of 150 deliveries. Of those, 22 (76%) met one of the two sets of eligibility conditions. This partner was unable to randomly allocate sites to a study arm due to local political constraints, as the Ministry of Health feared community fatigue due to the large number of organizations implementing projects and conducting research. As such, the partner worked with the Ministry of Health to identify 10 intervention sites using the same eligibility criteria. They then selected comparison sites, matched to intervention sites on annual delivery volume and distance to a referral hospital. Sites with an existing infrastructure that functioned as a MWH, were not considered as an option for comparison sites. After selecting sites, both partners then constructed the core MWH model at each of the 20 intervention sites.

### Data sources

Population data are being collected from two main sources: household surveys (HHS) and in-depth interviews (IDIs). Baseline data collection occurred in early 2016 prior to the implementation of the MWH model in intervention clusters; endline data collection will occur in late 2018, after an 18-month intervention period. The HHS is administered to a sample of 2,400 recently delivered women

(eligibility criteria described below) residing in intervention and control clusters. In the case of maternal death, the household head or senior woman was interviewed as a proxy participant.

The HHS captures information on the domains and data fields seen in Table 2. The HHS was pretested among a sample of 50 participants representing all the major local languages. At baseline, only small adjustments were made in response to the pre-test, primarily changing formal translations into the vernacular.

**Table 2.** Summary table of data fields collected from the household survey

<b>Household Panel:</b>	<ul style="list-style-type: none"> <li>• Geo-coordinates of household/distance from nearest health facility</li> <li>• Age and sex of household members</li> <li>• Education level of household members</li> <li>• Recent pregnancy/delivery of household members</li> </ul>
<b>Individual Demographics and Household Characteristics</b>	<ul style="list-style-type: none"> <li>• Number of pregnancies</li> <li>• Outcome of pregnancies</li> <li>• Number of living/deceased children</li> <li>• Characteristics of living quarters (e.g., roof type, floor type, cooking fuel type)</li> <li>• Access to and quality of water</li> <li>• Household wealth indicators and assets</li> </ul>
<b>Last Pregnancy</b>	<ul style="list-style-type: none"> <li>• Antenatal care services utilized</li> <li>• HIV testing               <ul style="list-style-type: none"> <li>○ Status</li> <li>○ PMTCT*</li> </ul> </li> <li>• Perceived satisfaction with antenatal care</li> </ul>
<b>Last Delivery</b>	<ul style="list-style-type: none"> <li>• Location of last delivery               <ul style="list-style-type: none"> <li>○ Decision-maker in location of delivery</li> <li>○ Mode of transportation</li> </ul> </li> <li>• Referral and bypassing</li> <li>• Receipt of CEmONC services (C-section, blood transfusion, IV antibiotics)</li> <li>• Perceived quality/satisfaction with delivery services</li> <li>• Maternal and neonatal vital status</li> </ul>
<b>Use of MWH</b>	<ul style="list-style-type: none"> <li>• Knowledge of MWH</li> <li>• Source of knowledge of MWH</li> <li>• Nearest MWH to home</li> <li>• Use of MWH before/after last delivery               <ul style="list-style-type: none"> <li>○ Cost of using mother's shelter</li> <li>○ Perceived quality of mother's shelter (safety, comfort, management and services)</li> <li>○ Satisfaction with mother's shelter</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>• Prior use of MWH</li> <li>• Intended future use of MWH</li> </ul>
<b>Cost of Delivery and Delivery Planning</b>	<ul style="list-style-type: none"> <li>• Planned or intended location for delivery <ul style="list-style-type: none"> <li>○ Adherence to planned or intended location for delivery</li> </ul> </li> <li>• Barriers to birth plan adherence</li> <li>• Savings for last delivery</li> <li>• Cost of last delivery (broken down by expense)</li> </ul>
<b>Postnatal Care (PNC) and infant health</b>	<ul style="list-style-type: none"> <li>• Time to first maternal and newborn post-natal visit after delivery</li> <li>• Perceived quality of post-natal services received</li> <li>• Breastfeeding practices</li> <li>• Supplementary feeding practices</li> <li>• Newborn vaccination status</li> <li>• PMTCT/ART<sup>++</sup> for newborn</li> <li>• Interactions between the parent and the child</li> <li>• Maternal depression assessment</li> <li>• Health seeking behavior for child's last illness</li> </ul>
<b>Health Care Knowledge and Beliefs</b>	<ul style="list-style-type: none"> <li>• Use of contraceptives for family planning</li> <li>• Primary barriers to accessing health care <ul style="list-style-type: none"> <li>○ Primary barriers to accessing skilled delivery services</li> </ul> </li> </ul>

\* PMTCT = Prevention of mother-to-child transmission of HIV; <sup>++</sup>ART = Antiretroviral therapy

In-depth interviews are conducted among a subsample of 240 HHS participants in order to gain a deeper understanding of community awareness, perceptions and experiences. Because the seven districts are spread out and culturally different, we wanted to ensure we reached saturation or predictability in each district to better explore context with the qualitative data.[32] Consequently, we planned to conduct a large number of in-depth interviews to make sure there was sufficient coverage of different populations to provide insight into the quantitative survey findings. IDI content builds upon themes captured in the HHS and includes perceptions of labor and delivery practices, barriers to accessing care, knowledge and awareness of MWHs, sources of knowledge of MWH, perceptions of the quality of maternity homes (safety, comfort, management and services), perceptions of MWH ownership, perceptions of health facility, and expenses incurred for last delivery.

The population-based approach captures the experiences of those who utilized the facility in their catchment, other facilities, and those who did not access a facility for delivery, allowing us to more

accurately estimate the impact of the MWH model intervention among women living farthest from the health facility in an intention-to-treat analysis.

### Sampling strategy and sample size

To estimate the impact of the MWH model based on an intention-to-treat analysis, we aim to select a representative sample of women in our sample frame who delivered a baby in the past 12 months, irrespective of her place of delivery or her use of a MWH. With this strategy, we will also be able to explore the relationship between use of the MWH and location of delivery. As such, we are recruiting a repeated cross-section of 2,400 households at each round for the survey (approximately 60 households per cluster): 1,200 from both intervention and control sites at both baseline (completed in 2016) and endline (planned for 2018), for a total study sample of 4,800 households (Table 3).

**Table 3:** Total sample size for evaluation

<i>Evaluation Activity</i>	<i>Intervention Sites</i>	<i>Comparison Sites</i>	<i>Households per Site</i>	<i>X2 Observations (baseline &amp; endline)</i>	<i>Total</i>
<i>Household Survey</i>	20	20	60	2	4800
<i>In-depth Interview*</i>	20	20	6	2	480
<b>TOTAL PARTICIPANTS FOR ALL EVALUATION ACTIVITIES:</b>					<b>4800</b>
<i>*Note that IDIs are a subset of the total household survey population selected for more in-depth information and are therefore NOT factored in as additional human subject participants in the total sample size for this study.</i>					

After accounting for the clustered sampling design (ICC estimated at 0.04 based on previous work [33–35]), and assuming an alpha of .05, this sample will provide us with 80% power to detect a minimum 10 percentage point difference in the anticipated impact of the MWH intervention on the primary outcome of facility delivery, a programmatically meaningful difference. We recruited a sample of 240 women for the IDIs (randomly selecting 10% of the household sample) at baseline, and will recruit another 240 at endline.

## Participant recruitment

For the purposes of this evaluation, a household is defined as a group of people who regularly cook together. Inclusion criteria for the household survey are:

- Household with someone who has delivered a baby within the past 12 months, irrespective of maternal or infant vital status
- Participant must be age 15 or older. If age 15-17, a legal guardian must be available for consent.
- Proxy participant (if woman deceased) must be over the age of 18
- Resident of the village identified for sampling ( $\geq 10$  km from the facility)

To select a sample representative of women living at least 10km from our health facility, we employ multi-stage random sampling procedures (Figure 3). We begin the first stage of sampling by visiting every village within the catchment area of each study site, informing the local village leader of the purpose of the study and taking the GPS coordinates from the approximate geographical “center” of the village. We input these GPS coordinates into ArcGIS® Online (Esri, Redlands, CA) and use the line creation tool to draw the most direct route along the roads and paths visible on the World Imagery basemap between each village center and their associated health facility. We then use this network of roads to calculate the distance of each village to the health facility and develop a sampling frame of all villages within each catchment area located more than 10km from the health facility (rounding up from 9.5km). We then randomly select a sample of 10 villages from each catchment area with probability proportional to population size. We list every eligible village within a catchment area in Microsoft Excel® along with the total population of the village. We assign a series of numbers to each village, corresponding to the population size (i.e. if village 1 had 30 people, 1-30; village 2 had 20 inhabitants, 31-50), and use the random number generator function to select the villages in each catchment area.





1  
2  
3 consents separately, enrolls in the study, and completes the HHS in a private space where she feels  
4 comfortable. Completion of the HHS takes approximately 45 minutes.  
5  
6

7  
8 Of the woman participants, 10% are randomly selected to participate in a 30-minute IDI  
9 immediately following the survey. IDI participants can take a short break after the HHS, or reschedule if  
10 more convenient. The household-level sampling procedures described here have been conducted at  
11 baseline (2016) and will be conducted at endline (2018) with a new cross-sectional sample of  
12 households and women within the households. Therefore, the same households are not followed over  
13 time.  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Patient and public involvement**

24  
25  
26 The development of the research question and outcome measures were informed by key  
27 stakeholders and patients' experience and preferences derived from free list responses, key informant  
28 interviews, and focus group discussions conducted during the formative evaluation [24–26]. Input from  
29 key stakeholders and community members helped to ensure that the design of the intervention would  
30 be responsive to community standards of acceptability of factors such as safety and comfort, and a  
31 feasible option to increase facility deliveries. Patients were not involved in study design, recruitment,  
32 and or conduct of the trial. Given the nature of the intervention, there was limited potential burden on  
33 patients and therefore, the burden of the randomized controlled trial was not assessed by the patients.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 The primary audience for this evaluation is the Government of Zambia, particularly the Ministry  
45 of Health, Ministry of Community Development, and the Ministry of Chiefs and Traditional Affairs, which  
46 will use the results to inform the development of maternal and child health strategies and policies in  
47 Zambia. We have disseminated the baseline findings to key stakeholders internal to Zambia and will  
48 disseminate the full study findings after endline. Many of the findings will likely be of broader interest  
49 throughout the region and globally where maternal mortality is high, resources are low, and access to  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 facility-based delivery remains an issue. As such, results of this evaluation will be disseminated as widely  
4  
5 as possible through open-access journals, websites, and international conferences.  
6  
7  
8

## 9 10 **Procedures**

### 11 12 **Data collection**

13  
14 At baseline and endline, a local team of enumerators literate in the appropriate local  
15  
16 language(s) and in English are trained in qualitative and quantitative research methods and human  
17  
18 subjects' protection. Surveys are designed in SurveyCTO Collect software (Version 2.212; Doherty, Inc.)  
19  
20 and are captured electronically using encrypted tablets. The IDIs are digitally captured on audio  
21  
22 recorders. Enumerators explain the tablet system to all participants and explain the digital audio  
23  
24 recorders to those selected for IDIs.  
25  
26

27  
28 Several checks assure the quality of collected survey data. First, enumerators participate in an  
29  
30 extensive 5-day training. Second, the enumerators are overseen by data collection team leads with  
31  
32 greater experience in data collection fieldwork. Team leads are overseen by a field supervisor. Team  
33  
34 leads and the field supervisors review surveys for accuracy and completeness nightly. Third, field  
35  
36 supervisors randomly select a 5% subsample of households to be audited; the auditor revisits these  
37  
38 households and repeats a subset of survey questions that are checked for reliability. Fourth, the field  
39  
40 supervisors conduct a short nightly debrief with the data leads who each oversee three other data  
41  
42 collectors and are responsible for conducting the IDIs. Debriefs cover the following topics: field  
43  
44 challenges, sampling, total surveys conducted, and IDIs. Lastly, quantitative data are encrypted,  
45  
46 uploaded and transferred nightly to the data analysis team where progress is reviewed in real time. On a  
47  
48 nightly basis, qualitative data are removed from the recorders, saved on a password-protected  
49  
50 computer, and tracked nightly.  
51  
52  
53

### 54 55 **Data management**

1  
2  
3 Survey data are captured on tablets and saved to the internal memory. During each round of  
4 data collection, each evening, a data team supervisor reviews the survey and encrypts it so survey data  
5 are no longer accessible on the tablet. The supervisor uploads encrypted data nightly during the  
6 collection period to a secure server administered by SurveyCTO (Version 2.212; Doherty, Inc.). The  
7 evaluation team downloads the encrypted data using the SurveyCTO Client software (Version 2.212;  
8 Doherty, Inc.), and decrypts the data using a decryption key generated by the research team.  
9

10  
11 The evaluation team oversees data entry, management, and storage for qualitative data. All IDIs  
12 are translated into English and transcribed verbatim. Digital recorders and paper copies of written notes  
13 are kept in a locked cabinet until transcriptions are checked for accuracy and completeness, at which  
14 point audio files are deleted and notes are shredded. The electronic transcriptions do not contain  
15 identifying information, only a study ID number linked to the quantitative survey. A separate linking file  
16 for the quantitative and qualitative data is password protected and only accessible to the study team.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 **Data analysis**

33  
34 The primary independent variable of interest is assignment to the intervention. For the analysis,  
35 we will compare baseline characteristics between the intervention and control groups to assess balance.  
36 We collect data on potential confounders to increase precision, analyze heterogeneity, and, if necessary,  
37 control for any potential imbalance between the groups.  
38  
39  
40  
41  
42

43 The primary dependent variable is the probability of facility delivery for most recent birth, based  
44 on self-report by mothers. Secondary outcomes include:  
45

- 46 • Use of MWHs for antenatal care, delivery or postnatal services
- 47
- 48 • Delivery by caesarean section
- 49
- 50 • Maternal death
- 51
- 52 • Neonatal death
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 We initially considered other secondary morbidity outcomes, but because the data were self-  
4 reported and asked about experience up to 12 months before, there were limitations to what can  
5 reasonably be asked without introducing major recall bias. The survey captures additional indicators of  
6 complications including IV antibiotics, blood transfusions, and referral to CEmONC, but we have limited  
7 secondary outcomes to those most likely to be clearly remembered.  
8  
9  
10  
11  
12  
13

14 All quantitative analyses will be conducted in SAS v9.4 (SAS, Cary, NC). Our quantitative analytic  
15 plan is threefold, yielding descriptive, bivariate and multivariate statistics. First, we will describe the  
16 study sample, stratifying by intervention and control group and testing for differences between the  
17 groups. Second, we will estimate differences between the groups for primary and secondary outcomes,  
18 controlling for a set of baseline demographics. Categorical variables will be compared between the  
19 groups using a chi-squared test when cell sizes are sufficient or Fisher's exact test when the cell sizes are  
20 small; continuous variables will be compared using t-tests if normally distributed or non-parametric  
21 Wilcoxon rank sum tests if the distribution is non-normal. Third, we will fit several regression models to  
22 estimate the impact of the intervention on the primary and secondary outcomes, adjusting for baseline  
23 values, assignment matching variables, and any imbalanced covariates. To control for the phased timing  
24 of implementation, we include a variable in our main models that captures the month the home  
25 opened.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 All qualitative data will be analyzed in Nvivo 10 © software (QSR International Pty Ltd.). We will  
42 conduct a content analysis of the IDI transcripts. Coding themes have been identified *a priori*. Additional  
43 themes will be included as they emerge. We will triangulate findings with the quantitative data to  
44 identify consistencies, inconsistencies or additional themes to be explored. We will use the themes  
45 developed during the baseline analysis to analyze the endline data and identify any new themes as they  
46 emerge.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To systematically assess confounders and the risk of bias at the pre-intervention phase,  
4 intervention phase, and post-intervention phase, we will use the ROBINS-I tool.[36] Guided by this tool,  
5 we will transparently report threats to validity of this quasi-experimental study during analysis,  
6 interpretation and dissemination. Results for the primary and each secondary evaluation question will  
7 be presented.  
8  
9  
10  
11  
12  
13

## 14 **ETHICS**

### 15 **Ethics approval and consent to participate**

#### 16 **Ethical review boards**

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Prior to participant enrollment, ethical approvals were obtained from the Boston University Institutional Review Board (IRB), University of Michigan IRB (for a de-identified dataset only), and the ERES Converge Research IRB, a private local ethics board in Zambia. We also obtained official approval to proceed with the study from the Zambia National Health Research Authority, which is responsible for oversight of all research conducted in the country. Adverse events, unanticipated problems and any protocol changes will be reported to the IRBs and the Zambia National Health Research Authority per their guidelines, and all investigators will be informed.

#### Potential risks and protections

This study poses minimal risk to study participants and several steps were taken to minimize risk and burden. To reduce the risk of disclosure of personal or sensitive information enumerators are trained to stop participants from disclosing information that is too sensitive. Participation may cause some discomfort from answering certain questions, particularly if the maternal or neonatal health outcomes were adverse. Enumerators are trained to minimize any potential discomfort or harm to all participants during all study activities to the greatest extent possible. We minimize any waiting by participants by

1  
2  
3 scheduling meetings during times convenient to participants and interviews are kept to as short of time  
4  
5 as possible taking breaks if necessary.  
6  
7

## 8 Potential benefits 9

10  
11 There are no direct individual benefits to participating in the study. The evaluation results will  
12  
13 generate evidence on the impact of MWHs on facility delivery for those who live farthest away. Findings  
14  
15 will provide insight for policy makers into how, if found to be effective, MWHs can be part of a broader  
16  
17 strategy to improve maternal and neonatal health outcomes.  
18  
19

## 20 Participant confidentiality 21

22  
23 Throughout the study, we take care to ensure the confidentiality of data obtained from study  
24  
25 participants. The HHSs and IDIs are carried out in participants' private homes or somewhere the  
26  
27 participant feels comfortable. We do not proceed with data collection until we can confirm that the  
28  
29 location is acceptable and participants agree that they feel comfortable discussing study topics.  
30  
31

32  
33 The linking file with identifiable data and basic demographics is stored in a separate file within  
34  
35 the tablet system. Upon completion of data collection, all files are stored on a secure server during data  
36  
37 analysis and report writing. Only BU/RTC investigators have access to identifiable data. All analyses by  
38  
39 study partners are conducted on de-identified datasets per IRB approvals. Analyses are presented in  
40  
41 aggregate format in technical reports to stakeholders and in manuscripts submitted for publication in  
42  
43 scientific journals. Under no circumstances do organizations or individuals have access to the  
44  
45 participant's individual demographic information and potential identifying information (job title, age  
46  
47 range, sex, and village). As explained above, the qualitative data are de-identified, with basic  
48  
49 demographics only.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Informed consent

Prior to any data collection, we discuss the purpose of the study with local leaders so that the study activities are clearly understood. If a household is eligible, the study team proceeds with the informed voluntary consent process from the household head or the most senior woman in the household, introducing themselves, the purpose of the study, and explaining what we are asking of them in terms of participation, the risks and benefits, the right to withdraw without penalty at any time, that their information will be kept in a safe location, and that their answers will not be linked to their names. Participants are informed that the alternative is to not participate in the study. The study team slowly and clearly asks for consent to participate. If a selected household participant declines participation, the next household on the randomly ordered list of eligible households is contacted. If a household head or senior woman consents to participating, the study team documents written informed consent and proceeds with the interview. In addition to the household head or a senior woman, using the same process we also consent the woman selected from within the household to respond to the survey; in some cases, this may be the same person. A maximum of two individuals are consented per household.

We anticipate about 15% of the sample in each round to be between 15-17 years of age. In Zambia, 'emancipated minors' can enroll if they provide assent and their guardian or husband also provides consent. If a woman's husband is 18 or older, then he can provide informed consent on behalf of his wife; however, if he is also under 18 years old, then her legal guardian must provide consent. If under 18, the research team will allow the woman to first determine if she wishes to join the study (assent is provided) and then obtain consent by the guardian or husband. Thus, the individual's wishes are protected and she can determine if she wishes to be part of the study.

All informed consent or assent/consent is documented with a signature; in the event a participant cannot write, a witness signs the informed consent. A participant retains a copy of the



1  
2  
3 informed consent form. The informed consent and assent processes are always conducted in the  
4  
5 language most preferred by the participant.  
6  
7

## 8 9 **Costs and payments**

10  
11 For all activities, the participants volunteer only the time taken to complete this survey. There is  
12  
13 no cash payment provided to participants for any portion of the study. Participants receive pieces of  
14  
15 fabric as small tokens of appreciation in recognition of their time and opportunity costs, in line with local  
16  
17 IRB procedures.  
18  
19

## 20 21 22 **Limitations**

23  
24 This study has several limitations. First, half of study clusters could not be randomly assigned to  
25  
26 either the intervention or control group due to political constraints and concern by the government  
27  
28 about community fatigue. The selection bias resulting from the different assignment strategies is  
29  
30 partially mitigated by ensuring comparison sites are matched on the same criteria as the other sites.  
31  
32 Additionally, because one partner's comparison sites include existing MWHs as part of standard of care,  
33  
34 and the other partner excluded sites with existing MWHs, we will analyze the full sample as a quasi-  
35  
36 experimental CBA study and we will estimate the impact in both the non-randomized and randomized  
37  
38 subsamples to assess potential bias introduced by non-random assignment and the differences in  
39  
40 comparison site selection. Second, we limited household eligibility to those living at least 10 km from  
41  
42 the health facilities and will not be able to assess impact on women living nearer to facilities. However,  
43  
44 remote women are the primary target of the MWH model and stand to benefit the most from the  
45  
46 intervention. To manage this limitation, in separate process evaluation protocols, each partner is  
47  
48 collecting facility-based data to understand any changes in demographics among those utilizing facilities  
49  
50 for delivery using agreed upon indicators and data sources. Lastly, because there are two implementing  
51  
52 partners, there is a risk that the MWH model will be implemented differently across the sites. To  
53  
54  
55  
56  
57  
58  
59  
60

mitigate this risk, we have developed and agreed upon the precise elements of the MWH model based on both partners' formative research [24–26] and will be assessing implementation fidelity using harmonized tools in the companion process evaluation protocols.

## REFERENCES

- 1 The United Nations. Goal 3 .. Sustainable Development Knowledge Platform. <https://sustainabledevelopment.un.org/sdg3> (accessed 2 Feb 2018).
- 2 Central Statistical Office (CSO) Zambia, [Ministry of Health (MOH) [Zambia], ICF International. Zambia Demographic and Health Survey 2013-14. Rockville, Maryland, USA: 2014.
- 3 UN General Assembly. Resolution adopted by the General Assembly on 25 September 2015 70/1. Transforming our world: the 2030 Agenda for Sustainable Development. 2030. [http://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A\\_RES\\_70\\_1\\_E.pdf](http://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A_RES_70_1_E.pdf) (accessed 17 Jan 2018).
- 4 Republic of Zambia Ministry of Health. National Health Strategic Plan 2011 - 2015. 2011;:119.
- 5 Republic of Zambia Ministry of Health. Roadmap for Accelerating Reduction of Maternal , Newborn and Child Mortality , 2013-2016. 2016;:2013–6.
- 6 Gabrysch S, Cousens S, Cox J, *et al*. The influence of distance and level of care on delivery place in rural Zambia: a study of linked national data in a geographic information system. *PLoS Med* 2011;**8**. doi:10.1371/journal.pmed.1000394
- 7 Gabrysch S, Campbell OM, Lawn J, *et al*. Still too far to walk: Literature review of the determinants of delivery service use. *BMC Pregnancy Childbirth* 2009;**9**:34. doi:10.1186/1471-2393-9-34
- 8 Lohela TJ, Campbell OMR, Gabrysch S, *et al*. Distance to Care, Facility Delivery and Early Neonatal Mortality in Malawi and Zambia. *PLoS One* 2012;**7**:e52110. doi:10.1371/journal.pone.0052110
- 9 Sialubanje C, Massar K, Hamer DH, *et al*. Understanding the psychosocial and environmental factors and barriers affecting utilization of maternal healthcare services in Kalomo, Zambia: A qualitative study. *Health Educ Res* 2014;**29**:521–32. doi:10.1093/her/cyu011
- 10 Stekelenburg J, Van Lonkhuijzen L, Spaans W, *et al*. Maternity waiting homes in rural districts in Africa: A cornerstone of safe motherhood? *Curr Womens Health Rev* 2006;**2**:235–8. doi:10.2174/157340406778699914
- 11 Lori JR, Wadsworth AC, Munro ML, *et al*. Promoting access: The use of maternity waiting homes to achieve safe motherhood. *Midwifery* 2013;**29**:1095–102. doi:10.1016/j.midw.2013.07.020
- 12 Kelly J, Kohls E, Poovan P, *et al*. The role of a maternity waiting area (MWA) in reducing maternal mortality and stillbirths in high-risk women in rural Ethiopia. *BJOG* 2010;**117**:1377–83. doi:10.1111/j.1471-0528.2010.02669.x

- 1  
2  
3 13 Henry EG, Semrau K, Hamer DH, *et al.* The influence of quality maternity waiting homes  
4 on utilization of facilities for delivery in rural Zambia. *Reprod Health* 2017;**14**:68.  
5 doi:10.1186/s12978-017-0328-z  
6  
7 14 Fogliati P, Straneo M, Mangi S, *et al.* A new use for an old tool: maternity waiting homes  
8 to improve equity in rural childbirth care. Results from a cross-sectional hospital and  
9 community survey in Tanzania. *Health Policy Plan* 2017;**32**:1354–60.  
10 doi:10.1093/heapol/czx100  
11  
12 15 García Prado A, Cortez R. Maternity waiting homes and institutional birth in Nicaragua:  
13 policy options and strategic implications. *Int J Health Plann Manage* 2012;**27**:150–66.  
14 doi:10.1002/hpm.1107  
15  
16 16 Chandramohan D, Cutts F, Millard P. The effect of stay in a maternity waiting home on  
17 perinatal mortality in rural Zimbabwe. *J Trop Med Hyg* 1995;**98**:261–  
18 7.<http://www.ncbi.nlm.nih.gov/pubmed/7636923> (accessed 12 Dec 2016).  
19  
20 17 Chandramohan D, Cutts F, Chandra R. Effects of a maternity waiting home on adverse  
21 maternal outcomes and the validity of antenatal risk screening. *Int J Gynecol Obstet*  
22 1994;**46**:279–84. doi:10.1016/0020-7292(94)90406-5  
23  
24 18 Gaym A, Pearson L, Soe KWW. Maternity waiting homes in Ethiopia--three decades  
25 experience. *Ethiop Med J* 2012;**50**:209–19.  
26  
27 19 Van Lonkhuijzen L, Stegeman M, Nyirongo R, *et al.* Use of Maternity Waiting Home in  
28 Rural Zambia. *Afr J Reprod Health* 2003;**7**:32–6. doi:10.1108/10650750910961929  
29  
30 20 Andemichael G, Haile B, Kosia A, *et al.* Maternity waiting homes: A panacea for  
31 maternal/neonatal conundrums in Eritrea. *J Eritrean Med Assoc* 2009;**4**:18–21.  
32 doi:10.4314/jema.v4i1.52112  
33  
34 21 van Lonkhuijzen L, Stekelenburg J, van Roosmalen J. Maternity waiting facilities for  
35 improving maternal and neonatal outcome in low-resource countries. *Cochrane database*  
36 *Syst Rev* 2012;**10**:CD006759. doi:10.1002/14651858.CD006759.pub3  
37  
38 22 Wild K, Barclay L, Kelly P, *et al.* The tyranny of distance: maternity waiting homes and  
39 access to birthing facilities in rural Timor-Leste. *Bull World Health Organ* 2012;**90**:97–  
40 103. doi:10.2471/BLT.11.088955  
41  
42 23 Ministry of Health (MOH) [Zambia]. Zambia National Health Strategic Plan 2017-2021.  
43 2017.  
44  
45 24 Chibuye PS, Bazant ES, Wallon M, *et al.* Experiences with and expectations of maternity  
46 waiting homes in Luapula Province, Zambia: a mixed-methods, cross-sectional study with  
47 women, community groups and stakeholders. *BMC Pregnancy Childbirth* 2018;**18**:42.  
48 doi:10.1186/s12884-017-1649-1  
49  
50 25 Lori JR, Munro-Kramer ML, Mdluli EA, *et al.* Developing a community driven sustainable  
51 model of maternity waiting homes for rural Zambia. *Midwifery* 2016;**41**:89–95.  
52 doi:10.1016/j.midw.2016.08.005  
53  
54 26 Scott NA, Vian T, Kaiser JL, *et al.* Listening to the community: Using formative research to  
55 strengthen maternity waiting homes in Zambia. *PLoS One* 2018;**13**. doi:<https://doi.org/10.1371/journal.pone.0194535>  
56  
57 27 Central Statistical Office (CSO) Zambia. 2010 Census of Population and Housing -  
58 Southern Province Analytical Report. Lusaka: 2014.  
59 <http://web0.psa.gov.ph/statistics/census/population-and-housing>  
60

- 1  
2  
3 28 Central Statistical Office (CSO) Zambia. 2010 Census of Population and Housing - Eastern  
4 Province Analytical Report. Lusaka: 2014.  
5 [https://www.zamstats.gov.zm/phocadownload/2010\\_Census/2010\\_Census\\_Analytical\\_Reports/Eastern Province Analytical Report - 2010 Census.pdf](https://www.zamstats.gov.zm/phocadownload/2010_Census/2010_Census_Analytical_Reports/Eastern%20Province%20Analytical%20Report%20-%202010%20Census.pdf) (accessed 19 Jan 2018).  
6  
7 29 Central Statistical Office (CSO) Zambia. Zambia 2010 Census of Population and Housing  
8 Population Summary Report. Lusaka: 2012. [http://www.mcaz.gov.zm/wp-](http://www.mcaz.gov.zm/wp-content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf)  
9 [content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf](http://www.mcaz.gov.zm/wp-content/uploads/2014/10/2010-Census-of-Population-Summary-Report.pdf) (accessed 19  
10 Jan 2018).  
11  
12 30 Zambian Ministry of Health. The 2012 List of Health Facilities in Zambia: Preliminary  
13 Report, v15. 2013;:252.  
14  
15 31 SMGL. Saving Mothers Giving Life - Home.  
16 2016.<https://www.savingmothersgivinglife.org/> (accessed 16 Nov 2016).  
17  
18 32 Bernard HR. *Social Research Methods Qualitative and Quantitative Approaches*. 2nd ed.  
19 USA: : SAGE Publications, Inc 2013.  
20  
21 33 Hamer DH, Herlihy JM, Musokotwane K, *et al*. Engagement of the Community,  
22 Traditional Leaders, and Public Health System in the Design and Implementation of a  
23 Large Community-Based, Cluster-Randomized Trial of Umbilical Cord Care in Zambia. *Am*  
24 *J Trop Med Hyg* 2015;**92**:666–72. doi:10.4269/ajtmh.14-0218  
25  
26 34 Semrau KEA, Herlihy J, Grogan C, *et al*. Effectiveness of 4% chlorhexidine umbilical cord  
27 care on neonatal mortality in Southern Province, Zambia (ZamCAT): a cluster-randomised  
28 controlled trial. *Lancet Glob Heal* 2016;**4**:e827–36. doi:10.1016/S2214-109X(16)30215-7  
29  
30 35 Pagel C, Prost A, Lewycka S, *et al*. Intracluster correlation coefficients and coefficients of  
31 variation for perinatal outcomes from five cluster-randomised controlled trials in low and  
32 middle-income countries: results and methodological implications. *Trials* 2011;**12**:151.  
33 doi:10.1186/1745-6215-12-151  
34  
35 36 Sterne JA, Hernán MA, Reeves BC, *et al*. ROBINS-I: a tool for assessing risk of bias in non-  
36 randomised studies of interventions. *BMJ* 2016;**355**:i4919. doi:10.1136/BMJ.I4919  
37

## 38 **AUTHORS STATEMENT**

39  
40  
41 NS led the scientific design, implementation, and was primarily responsible for drafting this manuscript.

42  
43 JK contributed to the development of the protocol, led the development of the study sample,  
44 coordinated data collection, and contributed to revisions of the manuscript. TV and RB contributed to  
45 the revisions and science of the protocol and data collection instruments. RF contributed to the  
46 development of the protocol, implemented the electronic data capture system, and contributed to the  
47 revisions of this manuscript. TN, GB, CB, and JL provided feedback on the protocol and reviewed and  
48 edited the final manuscript. DH provided scientific support, technical input into the survey design and  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 critically reviewed and edited the final manuscript. PR helped conceptualize the scientific design of the  
4  
5 study, provided technical input into the survey design, sampling approach, and critically reviewed and  
6  
7 edited the final manuscript. All authors read and approved the final version of the manuscript.  
8  
9

## 10 **FUNDING**

11  
12 This program was developed and is being implemented in collaboration with *MSD for Mothers*, MSD's  
13  
14 10-year, \$500 million initiative to help create a world where no woman dies giving life. *MSD for*  
15  
16 *Mothers* is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A. (MRK 1846-06500.COL). The  
17  
18 development of this article was additionally supported in part by the Bill & Melinda Gates Foundation  
19  
20 (OPP1130329) [https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-](https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/07/OPP1130329)  
21  
22 [Database/Grants/2015/07/OPP1130329](https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/07/OPP1130329) and The ELMA Foundation (ELMA-15-F0017)  
23  
24 <http://www.elmaphilanthropies.org/the-elma-foundation/>. The funders had no role in study design,  
25  
26 data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely  
27  
28 the responsibility of the authors and does not reflect positions or policies of MSD, the Bill & Melinda  
29  
30 Gates Foundation or The ELMA Foundation.  
31  
32  
33  
34  
35  
36

## 37 **CONFLICTS OF INTEREST STATEMENT**

38  
39 The authors declare that they have no competing interests.  
40  
41  
42  
43

## 44 **FIGURE LEGEND**

45  
46 **Figure 1. Minimum Maternity Waiting Home Model in the Maternity Home Alliance for Intervention**

47  
48 **Sites (n=20).**

49  
50  
51 **Figure 2. Map of the Maternity Home Alliance Intervention and Control Study Sites by Partner**

52  
53 **Figure 3. Multi-stage Random Sampling Strategy for Baseline and Endline**  
54  
55  
56  
57  
58  
59  
60




Figure 1. Minimum Maternity Waiting Home Model in the Maternity Home Alliance for Intervention Sites (n=20).

101x66mm (300 x 300 DPI)




Figure 2. Map of the Maternity Home Alliance Intervention and Control Study Sites by Partner

173x144mm (300 x 300 DPI)

only




Figure 3. Multi-stage Random Sampling Strategy for Baseline and Endline

97x54mm (300 x 300 DPI)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___1___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___3,clinicaltrials.gov
	2b	All items from the World Health Organization Trial Registration Data Set	1-23 and on clinicaltrials.gov
Protocol version	3	Date and version identifier	___na___
Funding	4	Sources and types of financial, material, and other support	___23___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___1___
	5b	Name and contact information for the trial sponsor	___23___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___23___

1			
2			
3		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
4			_____na_____
5			
6			
7			
8			
9			
10			
11	<b>Introduction</b>		
12			
13	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
14			_____5,6_____
15		6b	Explanation for choice of comparators
16			_____8_____
17	Objectives	7	Specific objectives or hypotheses
18			_____5,6_____
19			
20	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
21			_____8_____
22			
23			
24	<b>Methods: Participants, interventions, and outcomes</b>		
25	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
26			_____7_____
27			
28	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
29			_____8,9,12_____
30			
31	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
32			_____6_____
33		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
34			_____na_____
35		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
36			_____na_____
37		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
38			_____na_____
39			
40			
41			
42			
43			
44			
45			
46			
47			

1				
2				
3	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	____ 6,7,16 ____
4				
5				
6				
7				
8	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	____ 11 ____
9				
10				
11	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	____ 11 ____
12				
13				
14	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	____ 13 ____
15				

### 16 **Methods: Assignment of interventions (for controlled trials)**

#### 17 Allocation:

18				
19				
20	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	____ 9, 12, 13, ____
21				
22				
23				
24				
25	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	____ na ____
26				
27				
28				
29	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	____ na ____
30				
31				
32				
33	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	____ na ____
34				
35				
36		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	____ na ____
37				
38				

### 39 **Methods: Data collection, management, and analysis**

1				
2				
3	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	_____6-14_____
4	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
5			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
6			Reference to where data collection forms can be found, if not in the protocol	
7				
8		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	_____na_____
9			collected for participants who discontinue or deviate from intervention protocols	
10				
11	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality	_____14, 15_____
12			(eg, double data entry; range checks for data values). Reference to where details of data management	
13			procedures can be found, if not in the protocol	
14				
15	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	_____15, 16_____
16			statistical analysis plan can be found, if not in the protocol	
17				
18		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____16_____
19				
20		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any	
21			statistical methods to handle missing data (eg, multiple imputation)	_____na_____
22				
23				
24	<b>Methods: Monitoring</b>			
25				
26	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of	_____na_____
27			whether it is independent from the sponsor and competing interests; and reference to where further details	
28			about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not	
29			needed	
30				
31		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim	_____na_____
32			results and make the final decision to terminate the trial	
33				
34	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse	_____16, 17_____
35			events and other unintended effects of trial interventions or trial conduct	
36				
37	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent	_____na_____
38			from investigators and the sponsor	
39				

**Ethics and dissemination**

1				
2				
3	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____16_____
4				
5				
6	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____16, 17_____
7				
8				
9				
10	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____18, 19_____
11				
12				
13		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____na_____
14				
15				
16	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____17, 18_____
17				
18				
19	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____23_____
20				
21				
22	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____18_____
23				
24				
25	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____na_____
26				
27				
28	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____19_____
29				
30				
31				
32		31b	Authorship eligibility guidelines and any intended use of professional writers	_____22, 23_____
33				
34		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____na_____
35				
36	<b>Appendices</b>			
37				
38	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_Can be provided upon request_
39				
40				
41				
42				
43				
44				
45				
46				
47				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____na_____
----------------------	----	--	--------------

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only